




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :		(11) International Publication Number:	WO 98/56913
C12N 15/12, 15/11, 5/10, C07K 14/47, 16/18, G01N 33/50, A01K 67/027, A61K 31/70, 38/17, 48/00		A1	(43) International Publication Date: 17 December 1998 (17.12.98)
(21) International Application Number: PCT/US98/12078		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 12 June 1998 (12.06.98)		Published <i>With international search report.</i>	
(30) Priority Data:			
60/049,990 13 June 1997 (13.06.97) US 60/053,040 18 July 1997 (18.07.97) US 60/066,173 18 November 1997 (18.11.97) US			
(71) Applicants: LUDWIG INSTITUTE FOR CANCER RESEARCH [CH/US]; 605 Third Avenue, New York, NY 10158 (US). JAPANESE FOUNDATION FOR CANCER RESEARCH [JP/JP]; 1-37-1, Kami-Ikebukuro 1-chome, Toshima-ku, Tokyo 170 (JP).			
(72) Inventors: MIYAZONO, Kohei; The Cancer Institute, Japanese Foundation for Cancer Research, 1-37-1, Kami-Ikebukuro 1-chome, Toshima-ku, Tokyo 170 (JP). KAWABATA, Masahiro; The Cancer Institute, Japanese Foundation for Cancer Research, 1-37-1, Kami-Ikebukuro 1-chome, Toshima-ku, Tokyo 170 (JP).			
(74) Agent: VAN AMSTERDAM, John, R.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).			

(54) Title: SMAD6 AND USES THEREOF



(57) Abstract

The invention describes nucleic acids encoding the Smad6 protein, including fragments and biologically functional variants thereof. Also included are polypeptides and fragments thereof encoded by such nucleic acids, and antibodies relating thereto. Methods and products for using such nucleic acids and polypeptides also are provided.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

SMAD6 AND USES THEREOF

Field of the Invention

This invention relates to nucleic acids and encoded polypeptides which interact with the
5 TGF- β superfamily receptor complexes and which are a negative regulators of TGF- β superfamily signalling. The invention also relates to agents which bind the nucleic acids or polypeptides. The invention further relates to methods of using such nucleic acids and polypeptides in the treatment and/or diagnosis of disease.

10

Background of the Invention

During mammalian embryogenesis and adult tissue homeostasis transforming growth factor β (TGF- β) performs pivotal tasks in intercellular communication (Roberts et al., *Growth Factors* 8:1-9, 1993). The cellular effects of this pleiotropic factor are exerted by ligand-induced hetero-oligomerization of two distantly related type I and type II serine/threonine kinase
15 receptors, T β R-I and T β R-II, respectively (Lin and Lodish, *Trends Cell Biol.* 11:972-978, 1993; Deryck, *Trends Biochem. Sci.* 19:548-553, 1994; Massague and Weis-Garcia, *Cancer Surv.* 27:41-64, 1996; ten Dijke et al., *Curr. Opin. Cell. Biol.* 8:139-145, 1996). The two receptors, which both are required for signalling, act in sequence; T β R-I is a substrate for the constitutively active T β R-II kinase (Wrana et al., *Nature* 370:341-347, 1994; Weiser et al., *EMBO J.* 14:2199-
20 2208, 1995).

TGF- β is the prototype of a large family of structurally related proteins that are involved in various biological activities (Massagué, et al., *Trends Cell Biol.* 7:187-192, 1997; Roberts & Sporn, in: Peptide growth factors and their receptors, Part I (Sporn, M.B. and Roberts, A.B., eds) pp. 319-472, Springer-Verlag, Heidelberg (1990); Yingling et al.,
25 *Biochim. Biophys. Acta* 1242:115-136, 1995). The TGF- β "superfamily" includes activins and bone morphogenetic proteins (BMPs) that signal in a similar fashion, each employing distinct complexes of type I and type II serine/threonine kinase receptors (Lin and Lodish, 1993; Deryck, 1994; Massague and Weis-Garcia, 1996; ten Dijke et al., 1996). TGF- β related molecules act in environments where multiple signals interact and are likely to be under tight
30 spatial and chronological regulation. For example, activin and BMP exert antagonistic effects in the development of *Xenopus* embryos (Graff et al., *Cell* 85:479-487, 1996). *Chordin* (Piccolo et al., *Cell* 86:589-598, 1996) and *noggin* (Zimmerman et al., *Cell* 86:599-606, 1996), for example, inhibit the ventralizing effect of BMP4 by binding specifically to the

ligand. Likewise, follistatin neutralizes the activity of activin (Hemmati-Brivalou et al., *Cell* 77:283-295, 1994).

Genetic studies of TGF- β -like signalling pathways in *Drosophila* and *Caenorhabditis elegans* have led to the identification of *mothers against dpp* (*Mad*) (Sekelsky et al., *Genetics* 139:1347-1358, 1995) and *sma* (Savage et al., *Proc. Natl. Acad. Sci. USA* 93:790-794, 1996) genes, respectively. The products of these related genes perform essential functions downstream of TGF- β -like ligands acting via serine/threonine kinase receptors in these organisms (Wiersdorff et al., *Development* 122:2153:2163, 1996; Newfeld et al., *Development* 122:2099-2108, 1996; Hoodless et al., *Cell* 85:489-500, 1996). Vertebrate homologs of *Mad* and *sma* have been termed *Smads* (Derynck et al., *Cell* 87:173, 1996) or MADR genes (Wrana and Attisano, *Trends Genet.* 12:493-496, 1996). Genetic alterations in *Smad2* and *Smad4/DPC4* have been found in specific tumor subsets, and thus *Smads* may function as tumor suppressor genes (Hahn et al., *Science* 271:350-353, 1996; Riggins et al., *Nature Genet.* 13:347-349, 1996; Eppert et al., *Cell* 86:543-552, 1996). Smad proteins share two regions of high similarity, termed MH1 and MH2 domains, connected with a variable proline-rich sequence (Massague, *Cell* 85:947-950, 1996; Derynck and Zhang, *Curr. Biol.* 6:1226-1229, 1996). The C-terminal part of Smad2, when fused to a heterologous DNA-binding domain, was found to have transcriptional activity (Liu et al., *Nature* 381:620-623, 1996; Meersseman et al., *Mech. Dev.* 61:127-1400, 1997). The intact Smad2 protein when fused to a DNA-binding domain, was latent, but transcriptional activity was unmasked after stimulation with ligand (Liu et al., 1996).

Different Smads specify different responses using functional assays in *Xenopus*. Whereas Smad1 induces ventral mesoderm, a BMP-like response, Smad2 induces dorsal mesoderm, an activin/TGF- β -like response (Graff et al., *Cell* 85:479-487, 1996; Baker and Harland, *Genes & Dev.* 10:1880-1889, 1996; Thomsen, *Development* 122:2359-2366, 1996). Upon ligand stimulation Smads become phosphorylated on serine and threonine residues; BMP stimulates Smad1 phosphorylation, whereas TGF- β induces Smad2 and Smad3 phosphorylation (Hoodless et al., *Cell* 85:489-500, 1996; Liu et al., 1996; Eppert et al., 1996; Lechleider et al., *J. Biol. Chem.* 271:17617-17620, 1996; Yingling et al., *Proc. Natl. Acad. Sci. USA* 93:8940-8944, 1996; Zhang et al., *Nature* 383:168-172, 1996; Macias-Silva et al., *Cell* 87:1215-1224, 1996; Nakao et al., *J. Biol. Chem.* 272:2896-2900, 1996).

Smad4 is a common component of TGF- β , activin and BMP signalling (Lagna et al., *Nature* 383:832-836, 1996; Zhang et al., *Curr. Biol.* 7:270-276, 1997; de Winter et al., *Oncogene* 14:1891-1900, 1997). Smad4 phosphorylation has thus far been reported only after

activin stimulation of transfected cells (Lagna *et al.*, 1996). After stimulation with TGF- β or activin Smad4 interacts with Smad2 or Smad3, and upon BMP challenge a heteromeric complex of Smad4 and Smad1 has been observed (Lagna *et al.*, 1996). Upon ligand stimulation, Smad complexes translocate from the cytoplasm to the nucleus (Hoodless *et al.*, 1996; Liu *et al.*, 1996; Baker and Harland, 1996; Macías-Silva *et al.*, 1996), where they, in combination with DNA-binding proteins, may regulate gene transcription (Chen *et al.*, *Nature* 383:691-696, 1996).

Summary of the Invention

The invention provides isolated nucleic acid molecules, unique fragments of those molecules, expression vectors containing the foregoing, and host cells transfected with those molecules. The invention also provides isolated polypeptides and agents which bind such polypeptides, including antibodies. The foregoing can be used in the diagnosis or treatment of conditions characterized by the expression of a Smad6 nucleic acid or polypeptide, or lack thereof. The invention also provides methods for identifying pharmacological agents useful in the diagnosis or treatment of such conditions. Here, we present the identification of Smad6, which inhibits phosphorylation of pathway specific Smad polypeptides including Smad2 and Smad1 and inhibits the TGF- β superfamily signalling pathway such as the TGF- β and BMP signalling pathways.

According to one aspect of the invention, an isolated nucleic acid molecule is provided. The molecule hybridizes under stringent conditions to a molecule consisting of the nucleic acid sequence of SEQ ID NO:1. The isolated nucleic acid molecule codes for a polypeptide which inhibits TGF- β , activin, or BMP signalling. The invention further embraces nucleic acid molecules that differ from the foregoing isolated nucleic acid molecules in codon sequence due to the degeneracy of the genetic code. The invention also embraces complements of the foregoing nucleic acids.

In certain embodiments, the isolated nucleic acid molecule comprises a molecule consisting of the nucleic acid sequence of SEQ ID NO:3 or consists essentially of the nucleic acid sequence of SEQ ID NO:1. Preferably, the isolated nucleic acid molecule consists of the nucleic acid sequence of SEQ ID NO:3,

According to another aspect of the invention, an isolated nucleic acid molecule is provided. The isolated nucleic acid molecule comprises a molecule consisting of a unique fragment of SEQ ID NO:3 between 12 and 1487 nucleotides in length and complements thereof, provided that the isolated nucleic acid molecule excludes sequences consisting only of SEQ ID

NO:4. In one embodiment, the isolated nucleic acid molecule consists of between 12 and 32 contiguous nucleotides of SEQ ID NO:1, or complements of such nucleic acid molecules. In preferred embodiments, the unique fragment is at least 14, 15, 16, 17, 18, 20 or 22 contiguous nucleotides of the nucleic acid sequence of SEQ ID NO:1, SEQ ID NO:3, or complements thereof.

According to another aspect of the invention, the invention involves expression vectors, and host cells transformed or transfected with such expression vectors, comprising the nucleic acid molecules described above.

According to still other aspects of the invention, transgenic non-human animals are provided. The animals include in certain embodiments the foregoing expression vectors. In certain preferred embodiments, the transgenic non-human animal includes a conditional Smad6 expression vector, such as an expression vector that increases expression of Smad6 in a tissue specific, development stage specific, or inducible manner. In other embodiments, the transgenic non-human animal has reduced expression of Smad6 nucleic acid molecules. In some embodiments, the transgenic non-human animal includes a Smad6 gene disrupted by homologous recombination. The disruption can be homozygous or heterozygous. In other embodiments, the transgenic non-human animal includes a conditional Smad6 gene disruption, such as one mediated by e.g. tissue specific, development stage specific, or inducible, expression of a recombinase. In yet other embodiments, the transgenic non-human animal includes a *trans*-acting negative regulator of Smad6 expression, such as antisense Smad6 nucleic acid molecules, nucleic acid molecules which encode dominant negative Smad6 proteins, Smad6 directed ribozymes, etc.

According to another aspect of the invention, an isolated polypeptide is provided. The isolated polypeptide is encoded by the isolated nucleic acid molecule of any of claims 1, 2, 3, or 4, and the polypeptide has TGF- β , activin, or BMP signalling inhibitory activity. Preferably, the isolated polypeptide consists of the amino acid sequence of SEQ ID NO:2.

In other embodiments, the isolated polypeptide consists of a fragment or variant of the foregoing which retains the activity of the foregoing.

According to another aspect of the invention, there are provided isolated polypeptides which selectively bind a Smad6 protein or fragment thereof, provided that the isolated polypeptide is not a TGF- β superfamily receptor, such as a TGF- β , activin or BMP type I receptor. The isolated polypeptide in certain embodiments binds to a polypeptide encoded by the isolated nucleic acid molecule of any of claims 1, 2, 3, or 4. Preferred isolated polypeptides bind

to an epitope defined by a polypeptide consisting of the amino acid sequence of SEQ ID NO:2. In other preferred embodiments, isolated binding polypeptides include antibodies and fragments of antibodies (e.g., Fab, F(ab)₂, Fd and antibody fragments which include a CDR3 region which binds selectively to the Smad6 polypeptides of the invention). In still other preferred 5 embodiments, the isolated polypeptide is a monoclonal antibody, a humanized antibody or a chimeric antibody.

The invention provides in another aspect an isolated complex of polypeptides. The isolated complex includes a TGF- β superfamily receptor or receptor complex bound to a polypeptide as claimed in claim 16. Preferably the isolated complex comprises a polypeptide 10 having the amino acid sequence of SEQ ID NO:2. In other preferred embodiments, the receptor or receptor complex is selected from the group consisting of T β RI, BMPR-IA, BMPR-IB, ActR-, IA, a complex of T β RI and T β RII, a complex of BMPR-IA and BMPR-II, a complex of BMPR-IB and BMPR-II, a complex of ActR-IA and BMPR-II and a complex of ActR-IA and ActR-II.

According to still another aspect of the invention, methods for reducing TGF- β 15 superfamily signal transduction in a mammalian cell are provided. The methods involve contacting a mammalian cell with an amount of an inhibitor of TGF- β superfamily signal transduction effective to reduce such signal transduction in the mammalian cell. Preferably the TGF- β superfamily signal transduction is mediated by a TGF β superfamily ligand, particularly TGF- β 1, activin, Vg1, BMP-4 and/or BMP-7. Other methods are provided for modulating 20 phosphorylation of pathway specific Smads (e.g. Smad1, Smad2, Smad3 and/or Smad5). Certain methods are provided for reducing phosphorylation of Smad1 or Smad2 in a mammalian cell by contacting the mammalian cell with an agent which reduces Smad1 or Smad2 phosphorylation, respectively. Still other methods are provided for increasing phosphorylation of Smad3 in a mammalian cell by contacting the mammalian cell with an agent which increases Smad3 25 phosphorylation. In certain embodiments of the foregoing methods, the agent is an isolated Smad6 polypeptide, such as a polypeptide encoded by a nucleic acid which hybridizes under stringent conditions or the nucleic acid of SEQ ID NO:1, or degenerates or complements thereto.

According to still another aspect of the invention, methods for modulating proliferation and/or differentiation of a cancer cell are provided. The methods involve contacting a cancer cell 30 with an amount of an isolated Smad6 polypeptide as described above, effective to reduce proliferation and/or differentiation of the cancer cell.

The invention in a further aspect provides methods for increasing TGF- β superfamily signal transduction in a mammalian cell. The mammalian cell is contacted with an agent that

selectively binds to an isolated nucleic acid molecule of the invention or an expression product thereof in an amount effective to increase TGF- β superfamily signal transduction. Preferably the TGF- β superfamily signal transduction is mediated by a TGF β superfamily ligand selected from the group consisting of TGF- β 1, activin, Vg1, BMP-4 and BMP-7. Preferred agents are
5 antisense Smad6 nucleic acids, including modified nucleic acids, and polypeptides including antibodies which bind to a Smad6 polypeptide including the amino acids of SEQ ID NO:2, and a dominant negative variant of the polypeptide of SEQ ID NO:2.

The invention in still another aspect provides compositions comprising a Smad6 polypeptide and a pharmaceutically acceptable carrier.

10 The invention in a further aspect involves a method for decreasing Smad6 TGF- β superfamily inhibitory activity in a subject. An agent that selectively binds to an isolated nucleic acid molecule of the invention or an expression product thereof is administered to a subject in need of such treatment, in an amount effective to decrease TGF β superfamily signal transduction inhibitory activity of Smad7 in the subject. Preferably the TGF β superfamily signal transduction
15 is mediated by a TGF β superfamily ligand selected from the group consisting of TGF- β 1, activin, Vg1, BMP-4 and BMP-7. Preferred agents are antisense nucleic acids, including modified nucleic acids, and polypeptides including antibodies which bind to the polypeptide including the amino acids of SEQ ID NO:2, and dominant negative variants of the polypeptide of SEQ ID NO:2.

20 According to yet another aspect of the invention, methods for treating a condition characterized by abnormal BMP activity are provided. The methods include administering to a subject in need of such treatment an effective amount of Smad6 or a Smad6 agonist or antagonist sufficient to restore the BMP activity to normal. In some embodiments, the condition is selected from the group consisting of ossification of the posterior longitudinal ligament and ossification
25 of the ligament flavum.

According to another aspect of the invention, methods for treating a condition characterized by abnormal TGF- β activity are provided. The methods include administering to a subject in need of such treatment an effective amount of Smad6 or a Smad6 agonist or antagonist sufficient to restore the TGF- β activity to normal. In certain embodiments, the condition is
30 selected from the group consisting of liver fibrosis including cirrhosis and veno-occlusive disease; kidney fibrosis including glomerulonephritis, diabetic nephropathy, allograft rejection and HIV nephropathy; lung fibrosis including idiopathic fibrosis and autoimmune fibrosis; skin fibrosis including systemic sclerosis, keloids, hypertrophic burn scars and eosinophilia-myalgia

syndrome; arterial fibrosis including vascular restenosis and atherosclerosis; central nervous system fibrosis including intraocular fibrosis; and other fibrotic diseases including rheumatoid arthritis and nasal polyposis.

In another aspect of the invention, methods for modulating the expression of cyclin A are provided. The methods include contacting a cell with Smad6 or an agonist or antagonist thereof, in an amount effective to modulate the expression of cyclin A. In some embodiments the cell is contacted with Smad6 or an agonist thereof, and the expression of cyclin A is increased. In other embodiments, the cell is contacted with an antagonist of Smad6, and the expression of cyclin A is decreased. Preferably the antagonist of Smad6 is selected from the group consisting of antibodies to Smad6, dominant negative variants of Smad6 and Smad6 antisense nucleic acids.

According to another aspect of the invention, methods are provided for identifying lead compounds for a pharmacological agent useful in the diagnosis or treatment of disease associated with Smad6 TGF- β superfamily signal transduction inhibitory activity. One set of methods involves forming a mixture of a Smad6 polypeptide, a TGF- β superfamily receptor or receptor complex, and a candidate pharmacological agent. The mixture is incubated under conditions which, in the absence of the candidate pharmacological agent, permit a first amount of specific binding of the TGF- β superfamily receptor or receptor complex by the Smad6 polypeptide. A test amount of the specific binding of the TGF- β superfamily receptor or receptor complex by the Smad6 polypeptide then is detected. Detection of an increase in the foregoing activity in the presence of the candidate pharmacological agent indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which increases the Smad6 TGF- β superfamily signal transduction inhibitory activity. Detection of a decrease in the foregoing activities in the presence of the candidate pharmacological agent indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which decreases Smad6 TGF- β superfamily signal transduction inhibitory activity. Another set of methods involves forming a mixture as above, adding further a pathway specific Smad polypeptide, and detecting first and test amounts of TGF- β superfamily induced phosphorylation of the pathway specific Smad polypeptide. Detection of an increase in the phosphorylation in the presence of the candidate pharmacological agent indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which decreases the Smad6 TGF- β superfamily signal transduction inhibitory activity. Detection of a decrease in the foregoing activities in the presence of the candidate pharmacological agent indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which increases Smad6 TGF- β

superfamily signal transduction inhibitory activity. Preferred Smad6 polypeptides include the polypeptides of claim 16. Preferably the TGF β superfamily receptor is selected from the group consisting of TGF β superfamily type I receptors, TGF β superfamily type II receptors, and complexes of TGF β superfamily type I receptors and TGF β superfamily type II receptors.

5 Preferred pathway specific Smad polypeptides include Smad1 and Smad2.

According to still another aspect of the invention, methods for increasing phosphorylation of Smad3 in a mammalian cell are provided. The methods include contacting the mammalian cell with an amount of an isolated Smad6 polypeptide effective to increase phosphorylation of Smad3 in the mammalian cell.

10 According to another aspect of the invention, methods for reducing heteromerization of Smad2 with Smad3 or Smad4 in a mammalian cell are provided. The methods include contacting the mammalian cell with an amount of an isolated Smad6 nucleic acid or polypeptide, or an agonist thereof, effective to reduce heteromerization of Smad2 with Smad3 or Smad4 in the mammalian cell.

15 The use of the foregoing compositions, nucleic acids and polypeptides in the preparation of medicaments also is provided.

In the foregoing compositions and methods, preferred members of the TGF- β superfamily are TGF- β 1, activin, Vg1, BMP-4 and BMP-7, and the preferred pathway specific Smad polypeptides are Smad1, Smad2, Smad3 and Smad5.

20 These and other objects of the invention will be described in further detail in connection with the detailed description of the invention.

Brief Description of the Figures

Fig. 1 is a representation of a photograph which depicts (A) the protein sequence 25 alignments of Smad6 (SEQ ID NO:2) with Smads 1-5 (SEQ ID NOs:6-10) and (B) the tissue distribution of mouse and human Smad6 in human (left) and a mouse (right) tissue blots.

Fig. 2 is a representation of a photograph which shows the binding of Smad6 to type I receptors; (A) T β R-I, (B) ActR-IB, (C) BMPR-IB.

Fig. 3 (panels A-D) is a representation of a photograph which demonstrates the effect of 30 Smad6 on the phosphorylation of Smad1, Smad 2 and Smad3.

Fig. 4 (panels A-C) is a representation of a photograph which demonstrates the effect of Smad6 on the heteromerization of Smad2, Smad3 and Smad4.

Fig. 5 (panels A-C) is a representation of a photograph which shows the effect of Smad6

on transcriptional responses of TGF- β .

Fig. 6 (panels A-C) is a representation of a photograph which shows the expression of Smad6 following stimulation of cells with BMP-2 (A), BMP-7/OP-1 (B) or TGF- β 1 (C).

5

Brief Description of the Sequences

SEQ ID NO:1 is the nucleotide sequence of the mouse Smad6 cDNA.

SEQ ID NO:2 is the amino acid sequence of the mouse Smad6 protein.

SEQ ID NO:3 is the nucleotide sequence of the coding region of the mouse Smad6 cDNA.

10 SEQ ID NO:4 is the nucleotide sequence of the Smad6-related cDNA having GenBank accession number U59914.

SEQ ID NO:5 is the amino acid sequence of the Smad6-related protein having GenBank accession number U59914.

SEQ ID NO:6 is the amino acid sequence of the Smad1 protein, shown in Fig.1.

15 SEQ ID NO:7 is the amino acid sequence of the Smad2 protein, shown in Fig.1.

SEQ ID NO:8 is the amino acid sequence of the Smad3 protein, shown in Fig.1.

SEQ ID NO:9 is the amino acid sequence of the Smad4 protein, shown in Fig.1.

SEQ ID NO:10 is the amino acid sequence of the Smad5 protein, shown in Fig.1.

20

Detailed Description of the Invention

It has previously been shown that Smad1, Smad2, Smad3, and Smad5 transduce ligand-specific signals. In addition, Smad4 acts as an essential common partner of these ligand-specific Smads. In the present work, Smad6 is reported as a member belonging to a third class of the Smad family. Smad6 has a quite distinct structure from the Smad1, Smad2, 25 Smad3, Smad4 and Smad5, and is believed to be a negative regulator in signaling of the TGF- β superfamily. Although not wishing to be bound by a precise mechanism, it is believed that the regulatory step by Smad6 is at the receptor level since Smad6 stably associates with the type I receptors.

The present invention in one aspect involves the cloning of a cDNA encoding a Smad6 30 protein which interacts with TGF- β superfamily receptors. The TGF- β superfamily members are well known to those of ordinary skill in the art and include TGF- β s, activins, bone morphogenetic proteins (BMPs), Vg1, Mullerian inhibitory substance (MIS) and growth/differentiation factors (GDFs). The sequence of the mouse Smad6 gene is presented as

SEQ ID NO:1, and the predicted amino acid sequence of this gene's protein product is presented as SEQ ID NO:2. Analysis of the sequence by comparison to nucleic acid and protein databases determined that Smad6 has a C-terminal domain (the MH2 domain) which is related to other Smad proteins (Fig.1).

5 The invention thus involves in one aspect Smad6 polypeptides, genes encoding those polypeptides, functional modifications and variants of the foregoing, useful fragments of the foregoing, as well as therapeutics relating thereto.

Homologs and alleles of the Smad6 nucleic acids of the invention can be identified by conventional techniques. For example, the human homolog of Smad6 can be isolated by
10 hybridizing a probe derived from SEQ ID NO:1 under stringent conditions a human cDNA library and selecting positive clones. The existence, size, and tissue distribution of a human homolog is demonstrated in the examples by Northern blot. Thus, an aspect of the invention is those nucleic acid sequences which code for Smad6 polypeptides and which hybridize to a nucleic acid molecule consisting of SEQ ID NO:1, under stringent conditions. The term
15 "stringent conditions" as used herein refers to parameters with which the art is familiar. Nucleic acid hybridization parameters may be found in references which compile such methods, e.g.
Molecular Cloning: A Laboratory Manual, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. More
20 specifically, stringent conditions, as used herein, refers, for example, to hybridization at 65°C in hybridization buffer (3.5 x SSC, 0.02% Ficoll, 0.02% polyvinyl pyrrolidone, 0.02% Bovine Serum Albumin, 2.5mM NaH₂PO₄(pH7), 0.5% SDS, 2mM EDTA). SSC is 0.15M sodium chloride/0.15M sodium citrate, pH7; SDS is sodium dodecyl sulphate; and EDTA is ethylenediaminetetraacetic acid. After hybridization, the membrane upon which the DNA is
25 transferred is washed at 2 x SSC at room temperature and then at 0.1 x SSC/0.1 x SDS at temperatures up to 65°C.

There are other conditions, reagents, and so forth which can be used, which result in a similar degree of stringency. The skilled artisan will be familiar with such conditions, and thus they are not given here. It will be understood, however, that the skilled artisan will be able to
30 manipulate the conditions in a manner to permit the clear identification of homologs and alleles of Smad6 nucleic acids of the invention. The skilled artisan also is familiar with the methodology for screening cells and libraries for expression of such molecules which then are routinely isolated, followed by isolation of the pertinent nucleic acid molecule and sequencing.

In general, homologs and alleles typically will share at least 40% nucleotide identity and/or at least 50% amino acid identity to SEQ ID NO:1 and SEQ ID NO:2, respectively, in some instances will share at least 50% nucleotide identity and/or at least 65% amino acid identity and in still other instances will share at least 60% nucleotide identity and/or at least 75% amino acid identity. Watson-Crick complements of the foregoing nucleic acids also are embraced by the invention.

In screening for Smad6 proteins, a Southern blot may be performed using the foregoing conditions, together with a radioactive probe. After washing the membrane to which the DNA is finally transferred, the membrane can be placed against X-ray film to detect the radioactive signal.

The invention also includes degenerate nucleic acids which include alternative codons to those present in the native materials. For example, serine residues are encoded by the codons: TCA, AGT, TCC, TCG, TCT and AGC. Each of the six codons is equivalent for the purposes of encoding a serine residue. Thus, it will be apparent to one of ordinary skill in the art that any of the serine-encoding nucleotide triplets may be employed to direct the protein synthesis apparatus, *in vitro* or *in vivo*, to incorporate a serine residue into an elongating Smad6 polypeptide. Similarly, nucleotide sequence triplets which encode other amino acid residues include, but are not limited to: CCA, CCC, CCG and CCT (proline codons); CGA, CGC, CGG, CGT, AGA and AGG (arginine codons); ACA, ACC, ACG and ACT (threonine codons); AAC and AAU (asparagine codons); and ATA, ATC and ATT (isoleucine codons). Other amino acid residues may be encoded similarly by multiple nucleotide sequences. Thus, the invention embraces degenerate nucleic acids that differ from the biologically isolated nucleic acids in codon sequence due to the degeneracy of the genetic code.

The invention also provides isolated unique fragments of SEQ ID NO:1 or complements of SEQ ID NO:1. A unique fragment is one that is a 'signature' for the larger nucleic acid. It, for example, is long enough to assure that its precise sequence is not found in molecules outside of the Smad6 nucleic acids defined above. Unique fragments can be used as probes in Southern blot assays to identify such nucleic acids, or can be used in amplification assays such as those employing PCR. As known to those skilled in the art, large probes such as 200 nucleotides or more are preferred for certain uses such as Southern blots, while smaller fragments will be preferred for uses such as PCR. Unique fragments also can be used to produce fusion proteins for generating antibodies or determining binding of the polypeptide fragments, as demonstrated in the Examples, or for generating immunoassay components. Likewise, unique fragments can

be employed to produce nonfused fragments of the Smad6 polypeptides, useful, for example, in the preparation of antibodies, in immunoassays, and as a competitive binding partner of the TGF- β receptor, activin receptor or BMP receptor and/or other polypeptides which bind to the Smad6 polypeptides, for example, in therapeutic applications. Unique fragments further can be
5 used as antisense molecules to inhibit the expression of Smad6 nucleic acids and polypeptides, particularly for therapeutic purposes as described in greater detail below.

As will be recognized by those skilled in the art, the size of the unique fragment will depend upon its conservancy in the genetic code. Thus, some regions of SEQ ID NO:1 and its complement will require longer segments to be unique while others will require only short
10 segments, typically between 12 and 32 nucleotides (e.g. 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 and 32 bases long). Excluding nucleic acid molecules consisting completely of the nucleotide sequence of SEQ ID NO:4 or fragments thereof (GenBank accession number U59914) which overlap SEQ ID NO:1, virtually any segment of SEQ ID NO:1, or complements thereof, that is 18 or more nucleotides in length will be unique.
15 A fragment which is completely composed of the sequence of SEQ ID NO:4 or fragments thereof is one which does not include any of the nucleotides unique to Smad6. Preferred longer unique fragments include those which are at least 35, 40, 45, 50, 55, 60, 65, 70, 75, 100, 150, 200, 250, 300, or 500 nucleotide in length. Particularly preferred are those unique fragments drawn completely from the portion of SEQ ID NO:3 which is not overlapped by SEQ ID NO:4.

20 The unique fragments of the invention exclude sequences identical with certain particular prior art nucleic acids or that are identical to only fragments thereof. It is intended that the claims not embrace such molecules which are in the prior art. For example, portions of prior art ESTs having GenBank accession numbers AA451501, AA046702, W72479, AA131352, AA131266, W41111, N48277, and the like, which are identical to the Smad6 sequence of the
25 invention are not unique fragments of Smad6. Thus, the nucleic acids which consist only of these sequences, or which consist only of fragments of these sequences, are considered to be within the prior art. Nucleic acids, however, which include any portion of the novel sequence of the invention are embraced by the invention, including sequences comprising contiguous portions of the novel sequences and the prior art sequences. Such sequences have unexpected properties, as described herein. In one embodiment the unique fragment does not include any portion of the excluded prior art sequences. Those skilled in the art are well versed in methods for selecting such sequences, typically on the basis of the ability of the unique fragment to selectively distinguish the sequence of interest from non-Smad6 nucleic acids. A comparison of
30

the sequence of the fragment to those on known data bases typically is all that is necessary, although *in vitro* confirmatory hybridization and sequencing analysis may be performed.

A unique fragment can be a functional fragment. A functional fragment of a nucleic acid molecule of the invention is a fragment which retains some functional property of the larger nucleic acid molecule, such as coding for a functional polypeptide, binding to proteins, regulating transcription of operably linked nucleic acids, and the like. One of ordinary skill in the art can readily determine using the assays described herein and those well known in the art to determine whether a fragment is a functional fragment of a nucleic acid molecule using no more than routine experimentation.

10 As mentioned above, the invention embraces antisense oligonucleotides that selectively bind to a nucleic acid molecule encoding a Smad6 polypeptide, to increase TGF- β superfamily signalling by reducing the amount of Smad6. This is desirable in virtually any medical condition wherein a reduction of Smad6 is desirable, e.g., to increase TGF- β signalling.

As used herein, the term "antisense oligonucleotide" or "antisense" describes an
15 oligonucleotide that is an oligoribonucleotide, oligodeoxyribonucleotide, modified oligoribonucleotide, or modified oligodeoxyribonucleotide which hybridizes under physiological conditions to DNA comprising a particular gene or to an mRNA transcript of that gene and, thereby, inhibits the transcription of that gene and/or the translation of that mRNA. The antisense molecules are designed so as to interfere with transcription or translation of a target
20 gene upon hybridization with the target gene or transcript. Those skilled in the art will recognize that the exact length of the antisense oligonucleotide and its degree of complementarity with its target will depend upon the specific target selected, including the sequence of the target and the particular bases which comprise that sequence. It is preferred that the antisense oligonucleotide be constructed and arranged so as to bind selectively with the target under physiological
25 conditions, i.e., to hybridize substantially more to the target sequence than to any other sequence in the target cell under physiological conditions. Based upon SEQ ID NO:1, or upon allelic or homologous genomic and/or cDNA sequences, one of skill in the art can easily choose and synthesize any of a number of appropriate antisense molecules for use in accordance with the present invention. In order to be sufficiently selective and potent for inhibition, such antisense
30 oligonucleotides should comprise at least 10 and, more preferably, at least 15 consecutive bases which are complementary to the target, although in certain cases modified oligonucleotides as short as 7 bases in length have been used successfully as antisense oligonucleotides (Wagner et al., *Nature Biotechnol.* 14:840-844, 1996). Most preferably, the antisense oligonucleotides

comprise a complementary sequence of 20-30 bases. Although oligonucleotides may be chosen which are antisense to any region of the gene or mRNA transcripts, in preferred embodiments the antisense oligonucleotides correspond to N-terminal or 5' upstream sites such as translation initiation, transcription initiation or promoter sites. In addition, 3'-untranslated regions may be targeted. Targeting to mRNA splicing sites has also been used in the art but may be less preferred if alternative mRNA splicing occurs. In addition, the antisense is targeted, preferably, to sites in which mRNA secondary structure is not expected (see, e.g., Sainio et al., *Cell Mol. Neurobiol.* 14(5):439-457, 1994) and at which proteins are not expected to bind. Finally, although SEQ ID NO:1 discloses a cDNA sequence, one of ordinary skill in the art may easily derive the genomic DNA corresponding to the cDNA of SEQ ID NO:1. Thus, the present invention also provides for antisense oligonucleotides which are complementary to the genomic DNA corresponding to SEQ ID NO:1. Similarly, antisense to allelic or homologous cDNAs and genomic DNAs are enabled without undue experimentation.

In one set of embodiments, the antisense oligonucleotides of the invention may be composed of "natural" deoxyribonucleotides, ribonucleotides, or any combination thereof. That is, the 5' end of one native nucleotide and the 3' end of another native nucleotide may be covalently linked, as in natural systems, via a phosphodiester internucleoside linkage. These oligonucleotides may be prepared by art recognized methods which may be carried out manually or by an automated synthesizer. They also may be produced recombinantly by vectors.

In preferred embodiments, however, the antisense oligonucleotides of the invention also may include "modified" oligonucleotides. That is, the oligonucleotides may be modified in a number of ways which do not prevent them from hybridizing to their target but which enhance their stability or targeting or which otherwise enhance their therapeutic effectiveness.

The term "modified oligonucleotide" as used herein describes an oligonucleotide in which (1) at least two of its nucleotides are covalently linked via a synthetic internucleoside linkage (i.e., a linkage other than a phosphodiester linkage between the 5' end of one nucleotide and the 3' end of another nucleotide) and/or (2) a chemical group not normally associated with nucleic acids has been covalently attached to the oligonucleotide. Preferred synthetic internucleoside linkages are phosphorothioates, alkylphosphonates, phosphorodithioates, phosphate esters, alkylphosphonothioates, phosphoramidates, carbamates, carbonates, phosphate triesters, acetamidates, carboxymethyl esters and peptides.

The term "modified oligonucleotide" also encompasses oligonucleotides with a covalently modified base and/or sugar. For example, modified oligonucleotides include

oligonucleotides having backbone sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3' position and other than a phosphate group at the 5' position. Thus modified oligonucleotides may include a 2'-O-alkylated ribose group. In addition, modified oligonucleotides may include sugars such as arabinose instead of ribose. The 5 present invention, thus, contemplates pharmaceutical preparations containing modified antisense molecules that are complementary to and hybridizable with, under physiological conditions, nucleic acids encoding Smad6 polypeptides, together with pharmaceutically acceptable carriers.

Antisense oligonucleotides may be administered as part of a pharmaceutical composition. Such a pharmaceutical composition may include the antisense oligonucleotides in combination 10 with any standard physiologically and/or pharmaceutically acceptable carriers which are known in the art. The compositions should be sterile and contain a therapeutically effective amount of the antisense oligonucleotides in a unit of weight or volume suitable for administration to a patient. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients. The term 15 "physiologically acceptable" refers to a non-toxic material that is compatible with a biological system such as a cell, cell culture, tissue, or organism. The characteristics of the carrier will depend on the route of administration. Physiologically and pharmaceutically acceptable carriers include diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials which are well known in the art.

20 As used herein, a "vector" may be any of a number of nucleic acids into which a desired sequence may be inserted by restriction and ligation for transport between different genetic environments or for expression in a host cell. Vectors are typically composed of DNA although RNA vectors are also available. Vectors include, but are not limited to, plasmids, phagemids and virus genomes. A cloning vector is one which is able to replicate in a host cell, and which is 25 further characterized by one or more endonuclease restriction sites at which the vector may be cut in a determinable fashion and into which a desired DNA sequence may be ligated such that the new recombinant vector retains its ability to replicate in the host cell. In the case of plasmids, replication of the desired sequence may occur many times as the plasmid increases in 30 copy number within the host bacterium or just a single time per host before the host reproduces by mitosis. In the case of phage, replication may occur actively during a lytic phase or passively during a lysogenic phase. An expression vector is one into which a desired DNA sequence may be inserted by restriction and ligation such that it is operably joined to regulatory sequences and may be expressed as an RNA transcript. Vectors may further contain one or more marker

sequences suitable for use in the identification of cells which have or have not been transformed or transfected with the vector. Markers include, for example, genes encoding proteins which increase or decrease either resistance or sensitivity to antibiotics or other compounds, genes which encode enzymes whose activities are detectable by standard assays known in the art (e.g., 5 luciferase, β -galactosidase or alkaline phosphatase), and genes which visibly affect the phenotype of transformed or transfected cells, hosts, colonies or plaques (e.g., green fluorescent protein). Preferred vectors are those capable of autonomous replication and expression of the structural gene products present in the DNA segments to which they are operably joined.

As used herein, a coding sequence and regulatory sequences are said to be "operably" 10 joined when they are covalently linked in such a way as to place the expression or transcription of the coding sequence under the influence or control of the regulatory sequences. If it is desired that the coding sequences be translated into a functional protein, two DNA sequences are said to be operably joined if induction of a promoter in the 5' regulatory sequences results in the transcription of the coding sequence and if the nature of the linkage between the two DNA 15 sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the coding sequences, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a promoter region would be operably joined to a coding sequence if the promoter region were capable of effecting transcription of that DNA sequence such that the resulting transcript might 20 be translated into the desired protein or polypeptide.

The precise nature of the regulatory sequences needed for gene expression may vary 25 between species or cell types, but shall in general include, as necessary, 5' non-transcribed and 5' non-translated sequences involved with the initiation of transcription and translation respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. Such 5' non-transcribed regulatory sequences especially will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined gene. Regulatory sequences may also include enhancer sequences or upstream activator sequences as desired. The vectors of the invention may optionally include 5' leader or signal sequences. The choice and design of an appropriate vector is within the ability and discretion of one of ordinary skill in the art.

30 Expression vectors containing all the necessary elements for expression are commercially available and known to those skilled in the art. See, e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, 1989. Cells are genetically engineered by the introduction into the cells of heterologous DNA (RNA) encoding

Smad6 polypeptide or fragment or variant thereof. That heterologous DNA (RNA) is placed under operable control of transcriptional elements to permit the expression of the heterologous DNA in the host cell.

Preferred systems for mRNA expression in mammalian cells are those such as pRc/CMV 5 (available from Invitrogen, Carlsbad, CA) that contain a selectable marker such as a gene that confers G418 resistance (which facilitates the selection of stably transfected cell lines) and the human cytomegalovirus (CMV) enhancer-promoter sequences. Additionally, suitable for expression in primate or canine cell lines is the pCEP4 vector (Invitrogen), which contains an Epstein Barr virus (EBV) origin of replication, facilitating the maintenance of plasmid as a 10 multicopy extrachromosomal element. Another expression vector is the pEF-BOS plasmid containing the promoter of polypeptide Elongation Factor 1 α , which stimulates efficiently transcription *in vitro*. The plasmid is described by Mishizuma and Nagata (*Nuc. Acids Res.* 18:5322, 1990), and its use in transfection experiments is disclosed by, for example, Demoulin 15 (*Mol. Cell. Biol.* 16:4710-4716, 1996). Still another preferred expression vector is an adenovirus, described by Stratford-Perricaudet, which is defective for E1 and E3 proteins (*J. Clin. Invest.* 90:626-630, 1992). The use of the adenovirus as an Adeno.P1A recombinant is 20 disclosed by Warnier et al., in intradermal injection in mice for immunization against P1A (*Int. J. Cancer*, 67:303-310, 1996).

The invention also embraces so-called expression kits, which allow the artisan to prepare 25 a desired expression vector or vectors. Such expression kits include at least separate portions of each of the previously discussed coding sequences. Other components may be added, as desired, as long as the previously mentioned sequences, which are required, are included.

The invention also permits the construction of Smad6 gene transgenics and "knock-outs" in cells and in animals, providing materials for studying certain aspects of TGF- β superfamily 25 signal transduction and the effects thereof on cellular, developmental and physiological processes.

The invention also provides isolated polypeptides, which include the polypeptide of SEQ 30 ID NO:2 and unique fragments of SEQ ID NO:2. Smad6 polypeptides are encoded by nucleic acids described above, e.g., those which hybridize to SEQ ID NO:1. Such polypeptides are useful, for example, alone or as fusion proteins to generate antibodies, as components of an immunoassay.

A unique fragment of a Smad6 polypeptide, in general, has the features and characteristics of unique fragments as discussed above in connection with nucleic acids. As will

be recognized by those skilled in the art, the size of the unique fragment will depend upon factors such as whether the fragment constitutes a portion of a conserved protein domain. Thus, some regions of SEQ ID NO:2 will require longer segments to be unique (e.g., 20, 30, 50, 75, and 100 amino acid long) while others will require only short segments, typically between 5 and 12 5 amino acids (e.g. 5, 6, 7, 8, 9, 10, 11 and 12 amino acids long). Virtually any segment of SEQ ID NO:2 which is not overlapped by SEQ ID NO:5, and that is 10 or more amino acids in length will be unique. A unique fragment of a Smad6 polypeptide excludes fragments completely composed of the amino acid sequence of SEQ ID NO:5 which overlaps SEQ ID NO:2. A fragment which is completely composed of the sequence of SEQ ID NO:5 is one which does not 10 include any of the amino acids unique to Smad6.

Unique fragments of a polypeptide preferably are those fragments which retain a distinct functional capability of the polypeptide. Functional capabilities which can be retained in a unique fragment of a polypeptide include interaction with antibodies, interaction with other polypeptides (such as TGF- β superfamily type I receptors) or fragments thereof, selective 15 binding of nucleic acids or proteins, and enzymatic activity. Those skilled in the art are well versed in methods for selecting unique amino acid sequences, typically on the basis of the ability of the unique fragment to selectively distinguish the sequence of interest from non-family members. A comparison of the sequence of the fragment to those on known data bases typically is all that is necessary.

20 The invention embraces variants of the Smad6 polypeptides described above. As used herein, a "variant" of a Smad6 polypeptide is a polypeptide which contains one or more modifications to the primary amino acid sequence of a Smad6 polypeptide. Modifications which create a Smad6 variant can be made to a Smad6 polypeptide 1) to reduce or eliminate an activity of a Smad6 polypeptide, such as binding to T β R-I; 2) to enhance a property of a Smad6 25 polypeptide, such as protein stability in an expression system or the stability of protein-protein binding; or 3) to provide a novel activity or property to a Smad6 polypeptide, such as addition of an antigenic epitope or addition of a detectable moiety. Modifications to a Smad6 polypeptide are typically made to the nucleic acid which encodes the Smad6 polypeptide, and can include deletions, point mutations, truncations, amino acid substitutions and additions of amino acids or 30 non-amino acid moieties. Alternatively, modifications can be made directly to the polypeptide, such as by cleavage, addition of a linker molecule, addition of a detectable moiety, such as biotin, addition of a fatty acid, and the like. Modifications also embrace fusion proteins comprising all or part of the Smad6 amino acid sequence.

In general, variants include Smad6 polypeptides which are modified specifically to alter a feature of the polypeptide unrelated to its physiological activity. For example, cysteine residues can be substituted or deleted to prevent unwanted disulfide linkages. Similarly, certain amino acids can be changed to enhance expression of a Smad6 polypeptide by eliminating proteolysis by proteases in an expression system (e.g., dibasic amino acid residues in yeast expression systems in which KEX2 protease activity is present).

Mutations of a nucleic acid which encode a Smad6 polypeptide preferably preserve the amino acid reading frame of the coding sequence, and preferably do not create regions in the nucleic acid which are likely to hybridize to form secondary structures, such as hairpins or loops, which can be deleterious to expression of the variant polypeptide.

Mutations can be made by selecting an amino acid substitution, or by random mutagenesis of a selected site in a nucleic acid which encodes the polypeptide. Variant polypeptides are then expressed and tested for one or more activities to determine which mutation provides a variant polypeptide with the desired properties. Further mutations can be made to variants (or to non-variant Smad6 polypeptides) which are silent as to the amino acid sequence of the polypeptide, but which provide preferred codons for translation in a particular host. The preferred codons for translation of a nucleic acid in, e.g., *E. coli*, are well known to those of ordinary skill in the art. Still other mutations can be made to the noncoding sequences of a Smad6 gene or cDNA clone to enhance expression of the polypeptide. The activity of variants of Smad6 polypeptides can be tested by cloning the gene encoding the variant Smad6 polypeptide into a bacterial or mammalian expression vector, introducing the vector into an appropriate host cell, expressing the variant Smad6 polypeptide, and testing for a functional capability of the Smad6 polypeptides as disclosed herein. For example, the variant Smad6 polypeptide can be tested for inhibition of T β R-I (and/or activin or BMP receptor) signalling activity as disclosed in the Examples, or for inhibition of Smad 1 or Smad2 phosphorylation as is also disclosed herein. Preparation of other variant polypeptides may favor testing of other activities, as will be known to one of ordinary skill in the art.

The skilled artisan will also realize that conservative amino acid substitutions may be made in Smad6 polypeptides to provide functionally equivalent variants of the foregoing polypeptides, i.e., variants which retain the functional capabilities of the Smad6 polypeptides. As used herein, a "conservative amino acid substitution" refers to an amino acid substitution which does not alter the relative charge or size characteristics of the protein in which the amino acid substitution is made. Variants can be prepared according to methods for altering polypeptide

- sequence known to one of ordinary skill in the art such as are found in references which compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York.
- 5 Exemplary functionally equivalent variants of the Smad6 polypeptides include conservative amino acid substitutions of SEQ ID NO:2. Conservative substitutions of amino acids include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.

For example, one can make conservative amino acid substitutions to the amino acid sequence of the Smad6 polypeptide using methods known in the art. Exemplary methods for identifying functional variants of binding peptides are provided in a published PCT application of Strominger and Wucherpfennig (PCT/US96/03182, describes the identification of variants of HLA class II binding peptides). The described methods can be used to identify Smad6 variants which bind T β R-I or other TGF- β superfamily receptors or receptor complexes. These variants can be tested, e.g., for improved stability and are useful, *inter alia*, in regulation of TGF- β superfamily signalling.

Conservative amino-acid substitutions in the amino acid sequence of Smad6 polypeptides to produce functionally equivalent variants of Smad6 polypeptides typically are made by alteration of the nucleic acid encoding Smad6 polypeptides (SEQ ID NO:1). Such substitutions can be made by a variety of methods known to one of ordinary skill in the art. For example, amino acid substitutions may be made by PCR-directed mutation, site-directed mutagenesis according to the method of Kunkel (Kunkel, *Proc. Nat. Acad. Sci. U.S.A.* 82: 488-492, 1985), or by chemical synthesis of a gene encoding a Smad6 polypeptide. Where amino acid substitutions are made to a small unique fragment of a Smad6 polypeptide, such as a T β R-I binding site peptide, the substitutions can be made by directly synthesizing the peptide. The activity of functionally equivalent fragments of Smad6 polypeptides can be tested by cloning the gene encoding the altered Smad6 polypeptide into a bacterial or mammalian expression vector, introducing the vector into an appropriate host cell, expressing the altered Smad6 polypeptide, and testing for a functional capability of the Smad6 polypeptides as disclosed herein. Peptides which are chemically synthesized can be tested directly for function, e.g., for binding to T β R-I.

The invention as described herein has a number of uses, some of which are described elsewhere herein. First, the invention permits isolation of the Smad6 protein molecules (SEQ ID NO:2). A variety of methodologies well-known to the skilled practitioner can be utilized to

obtain isolated Smad6 molecules. The polypeptide may be purified from cells which naturally produce the polypeptide by chromatographic means or immunological recognition.

Alternatively, an expression vector may be introduced into cells to cause production of the polypeptide. In another method, mRNA transcripts may be microinjected or otherwise

5 introduced into cells to cause production of the encoded polypeptide. Translation of mRNA in cell-free extracts such as the reticulocyte lysate system also may be used to produce polypeptide. Those skilled in the art also can readily follow known methods for isolating Smad6 polypeptides. These include, but are not limited to, immunochromatography, HPLC, size-exclusion chromatography, ion-exchange chromatography and immune-affinity chromatography.

10 The invention also makes it possible isolate proteins such as T β R-I, ActR-IB and BMPR-IB by the binding of such proteins to Smad6 as disclosed herein. The identification of this binding also permits one of skill in the art to block the binding of Smad6 to other proteins, such as T β R-I. For example, binding of such proteins can be affected by introducing into a biological system in which the proteins bind (e.g., a cell) a polypeptide including a Smad6 T β R-I
15 binding site in an amount sufficient to reduce or even block the binding of Smad6 and T β R-I. The identification of Smad6 binding to TGF- β superfamily receptors also enables one of skill in the art to isolate Smad6 amino acid sequences which bind to such receptors and prepare modified proteins, using standard recombinant DNA techniques, which can bind to proteins such as T β R-I, ActR-IB and BMPR-IB. For example, when one desires to target a certain protein to a T β R-I
20 receptor complex, one can prepare a fusion polypeptide of the protein and the Smad6 T β R-I binding site. Additional uses are described further herein.

The invention also provides, in certain embodiments, "dominant negative" polypeptides derived from SEQ ID NO:2. A dominant negative polypeptide is an inactive variant of a protein, which, by interacting with the cellular machinery, displaces an active protein from its interaction
25 with the cellular machinery or competes with the active protein, thereby reducing the effect of the active protein. For example, a dominant negative receptor which binds a ligand but does not transmit a signal in response to binding of the ligand can reduce the biological effect of expression of the ligand. Likewise, a dominant negative catalytically-inactive kinase which interacts normally with target proteins but does not phosphorylate the target proteins can reduce
30 phosphorylation of the target proteins in response to a cellular signal. Similarly, a dominant negative transcription factor which binds to a promoter site in the control region of a gene but does not increase gene transcription can reduce the effect of a normal transcription factor by occupying promoter binding sites without increasing transcription.

The end result of the expression of a dominant negative polypeptide in a cell is a reduction in function of active proteins. One of ordinary skill in the art can assess the potential for a dominant negative variant of a protein, and using standard mutagenesis techniques to create one or more dominant negative variant polypeptides. For example, given the teachings contained 5 herein of a Smad6 polypeptide, one of ordinary skill in the art can modify the sequence of the Smad6 polypeptide by site-specific mutagenesis, scanning mutagenesis, partial gene deletion or truncation, and the like. See, e.g., U.S. Patent No. 5,580,723 and Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, 1989. The skilled artisan then can test the population of mutagenized polypeptides for diminution in a 10 selected activity (e.g., Smad6 reduction of TGF- β signalling activity) and/or for retention of such an activity. Other similar methods for creating and testing dominant negative variants of a protein will be apparent to one of ordinary skill in the art.

Dominant negative Smad6 proteins include variants in which a portion of the binding site of Smad6 for a TGF- β superfamily receptor has been mutated or deleted to reduce or eliminate 15 Smad6 interaction with the TGF- β receptor complex. Other examples include Smad6 variants in which the ability to inhibit phosphorylation of Smad1, Smad2 and/or Smad3 is reduced. One of ordinary skill in the art can readily prepare Smad6 variants bearing mutations or deletions in the C-terminal domain (e.g., in the MH2 domain) or in the N-terminal domain (e.g., in the glycine/glutamic acid residue rich region) and test such variants for a Smad6 activity.

20 The invention also involves agents such as polypeptides which bind to Smad6 polypeptides and to complexes of Smad6 polypeptides and binding partners such as T β R-I. Such binding agents can be used, for example, in screening assays to detect the presence or absence of Smad6 polypeptides and complexes of Smad6 polypeptides and their binding partners and in purification protocols to isolate Smad6 polypeptides and complexes of Smad6 polypeptides and 25 their binding partners. Such agents also can be used to inhibit the native activity of the Smad6 polypeptides or their binding partners, for example, by binding to such polypeptides, or their binding partners or both.

The invention, therefore, embraces peptide binding agents which, for example, can be antibodies or fragments of antibodies having the ability to selectively bind to Smad6 30 polypeptides. Antibodies include polyclonal and monoclonal antibodies, prepared according to conventional methodology.

Significantly, as is well-known in the art, only a small portion of an antibody molecule, the paratope, is involved in the binding of the antibody to its epitope (see, in general, Clark,

W.R. (1986) The Experimental Foundations of Modern Immunology Wiley & Sons, Inc., New York; Roitt, I. (1991) Essential Immunology, 7th Ed., Blackwell Scientific Publications, Oxford). The pFc' and Fc regions, for example, are effectors of the complement cascade but are not involved in antigen binding. An antibody from which the pFc' region has been enzymatically cleaved, or which has been produced without the pFc' region, designated an F(ab')₂ fragment, retains both of the antigen binding sites of an intact antibody. Similarly, an antibody from which the Fc region has been enzymatically cleaved, or which has been produced without the Fc region, designated an Fab fragment, retains one of the antigen binding sites of an intact antibody molecule. Proceeding further, Fab fragments consist of a covalently bound antibody light chain and a portion of the antibody heavy chain denoted Fd. The Fd fragments are the major determinant of antibody specificity (a single Fd fragment may be associated with up to ten different light chains without altering antibody specificity) and Fd fragments retain epitope-binding ability in isolation.

Within the antigen-binding portion of an antibody, as is well-known in the art, there are complementarity determining regions (CDRs), which directly interact with the epitope of the antigen, and framework regions (FRs), which maintain the tertiary structure of the paratope (see, in general, Clark, 1986; Roitt, 1991). In both the heavy chain Fd fragment and the light chain of IgG immunoglobulins, there are four framework regions (FR1 through FR4) separated respectively by three complementarity determining regions (CDR1 through CDR3). The CDRs, and in particular the CDR3 regions, and more particularly the heavy chain CDR3, are largely responsible for antibody specificity.

It is now well-established in the art that the non-CDR regions of a mammalian antibody may be replaced with similar regions of conspecific or heterospecific antibodies while retaining the epitopic specificity of the original antibody. This is most clearly manifested in the development and use of "humanized" antibodies in which non-human CDRs are covalently joined to human FR and/or Fc/pFc' regions to produce a functional antibody. Thus, for example, PCT International Publication Number WO 92/04381 teaches the production and use of humanized murine RSV antibodies in which at least a portion of the murine FR regions have been replaced by FR regions of human origin. Such antibodies, including fragments of intact antibodies with antigen-binding ability, are often referred to as "chimeric" antibodies.

Thus, as will be apparent to one of ordinary skill in the art, the present invention also provides for F(ab')₂, Fab, Fv and Fd fragments; chimeric antibodies in which the Fc and/or FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous

human or non-human sequences; chimeric F(ab'),₂ fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric Fab fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; and chimeric Fd fragment antibodies in which the FR and/or CDR1 and/or CDR2 regions have been replaced by homologous human or non-human sequences. The present invention also includes so-called single chain antibodies.

Thus, the invention involves polypeptides of numerous size and type that bind specifically to Smad6 polypeptides, and complexes of both Smad6 polypeptides and their binding partners. These polypeptides may be derived also from sources other than antibody technology. For example, such polypeptide binding agents can be provided by degenerate peptide libraries which can be readily prepared in solution, in immobilized form or as phage display libraries. Combinatorial libraries also can be synthesized of peptides containing one or more amino acids. Libraries further can be synthesized of peptoids and non-peptide synthetic moieties (e.g., peptidomimetics).

Phage display can be particularly effective in identifying binding peptides useful according to the invention. Briefly, one prepares a phage library (using e.g. m13, fd, or lambda phage), displaying inserts from 4 to about 80 amino acid residues using conventional procedures. The inserts may represent, for example, a completely degenerate or biased array. One then can select phage-bearing inserts which bind to the Smad6 polypeptide. This process can be repeated through several cycles of reselection of phage that bind to the Smad6 polypeptide. Repeated rounds lead to enrichment of phage bearing particular sequences. DNA sequence analysis can be conducted to identify the sequences of the expressed polypeptides. The minimal linear portion of the sequence that binds to the Smad6 polypeptide can be determined. One can repeat the procedure using a biased library containing inserts containing part or all of the minimal linear portion plus one or more additional degenerate residues upstream or downstream thereof. Yeast two-hybrid screening methods also may be used to identify polypeptides that bind to the Smad6 polypeptides. Thus, the Smad6 polypeptides of the invention, or a fragment thereof, can be used to screen peptide libraries, including phage display libraries, to identify and select peptide binding partners of the Smad6 polypeptides of the invention. Such molecules can be used, as described, for screening assays, for purification protocols, for interfering directly with the functioning of Smad6 and for other purposes that will be apparent to those of ordinary skill in the art.

A Smad6 polypeptide, or a fragment thereof, also can be used to isolate their native binding partners, including, e.g., the TGF- β receptor complex. Isolation of such binding partners may be performed according to well-known methods. For example, isolated Smad6 polypeptides can be attached to a substrate (e.g., chromatographic media, such as polystyrene beads, or a filter), and then a solution suspected of containing the TGF- β receptor complex may be applied to the substrate. If a TGF- β receptor complex which can interact with Smad6 polypeptides is present in the solution, then it will bind to the substrate-bound Smad6 polypeptide. The TGF- β receptor complex then may be isolated. Other proteins which are binding partners for Smad6, such as other Smads, and activin or BMP receptor complexes, may be isolated by similar 5 methods without undue experimentation.

It will also be recognized that the invention embraces the use of the Smad6 cDNA sequences in expression vectors, as well as to transfect host cells and cell lines, be these prokaryotic (e.g., *E. coli*), or eukaryotic (e.g., CHO cells, COS cells, yeast expression systems and recombinant baculovirus expression in insect cells). Especially useful are mammalian cells 15 such as human, mouse, hamster, pig, goat, primate, etc. They may be of a wide variety of tissue types, and include primary cells and cell lines. Specific examples include keratinocytes, fibroblasts, COS cells, peripheral blood leukocytes, bone marrow stem cells and embryonic stem cells. The expression vectors require that the pertinent sequence, i.e., those nucleic acids described *supra*, be operably linked to a promoter.

The isolation of the Smad6 gene also makes it possible for the artisan to diagnose a disorder characterized by aberrant expression of Smad6. These methods involve determining expression of the Smad6 gene, and/or Smad6 polypeptides derived therefrom. In the former situation, such determinations can be carried out via any standard nucleic acid determination assay, including the polymerase chain reaction, or assaying with labeled hybridization probes.

The invention further provides methods for reducing or increasing TGF- β superfamily signal transduction in a cell. Such methods are useful *in vitro* for altering the TGF- β signal transduction, for example, in testing compounds for potential to block aberrant TGF- β signal transduction or increase deficient TGF- β signal transduction. *In vivo*, such methods are useful for modulating growth, e.g., to treat cancer and fibrosis. Increasing TGF- β signal transduction in 25 a cell by, e.g., introducing a dominant negative Smad6 polypeptide or Smad6 antisense oligonucleotides in the cell, can be used to provide a model system for testing the effects of putative inhibitors of TGF- β signal transduction. Such methods also are useful in the treatment 30 of conditions which result from excessive or deficient TGF- β signal transduction. TGF- β signal

transduction can be measured by a variety of ways known to one of ordinary skill in the art, such as the reporter systems described in the Examples. Various modulators of Smad6 activity can be screened for effects on TGF- β signal transduction using the methods disclosed herein. The skilled artisan can first determine the modulation of a Smad6 activity, such as TGF- β signalling activity, and then apply such a modulator to a target cell or subject and assess the effect on the target cell or subject. For example, in screening for modulators of Smad6 useful in the treatment of cancer, cells in culture can be contacted with Smad6 modulators and the increase or decrease of growth or focus formation of the cells can be determined according to standard procedures. Smad6 activity modulators can be assessed for their effects on other TGF- β signal transduction 10 downstream effects by similar methods in many cell types.

Thus it can be of therapeutic benefit to administer Smad6 protein or nucleic acid encoding a Smad6 protein, or an agonist or antagonist of Smad6, to modulate TGF- β superfamily activity in certain conditions characterized by abnormal TGF- β superfamily activity. Specific examples of conditions involving abnormally elevated BMP activity include ossification of the 15 posterior longitudinal ligament (Yonemori et al., *Am. J. Pathol.* 150:1335-1347, 1997) and ossification of the ligament flavum (Hayashi et al., *Bone* 21:23-30, 1997). Specific examples of conditions involving abnormal TGF- β activity include liver fibrosis including cirrhosis and 20 veno-occlusive disease; kidney fibrosis including glomerulonephritis, diabetic nephropathy, allograft rejection and HIV nephropathy; lung fibrosis including idiopathic fibrosis and autoimmune fibrosis; skin fibrosis including systemic sclerosis, keloids, hypertrophic burn scars and eosinophilia-myalgia syndrome; arterial fibrosis including vascular restenosis and atherosclerosis; central nervous system fibrosis including intraocular fibrosis; and other fibrotic diseases including rheumatoid arthritis and nasal polyposis. (see, e.g., Border and Noble, *N. Engl. J. Med.* 331:1286-1292, 1994).

An effective amount of Smad6, or an agonist or antagonist thereof, is administered to treat the condition, which amount can be determined by one of ordinary skill in the art by routine experimentation. For example, to determine an effective amount of Smad6 for treating ossification, Smad6 can be administered and the progress of the ossification monitored using standard medical diagnostic methods. An amount of Smad6 which reduces the progression of 30 the ossification, or even halts the progression of the ossification is an effective amount. The person of ordinary skill in the art will be familiar with such methods. Other conditions involving abnormally elevated or reduced TGF- β superfamily activity can be treated in a like manner, by administering Smad6 or an agonist thereof, or a Smad6 antagonist, respectively, to reduce or

elevate the TGF- β superfamily activity into normal ranges as needed. Smad6 antagonists include the antibodies to Smad6, dominant negative variants of Smad6 and antisense Smad6 nucleic acids described above. Smad6 agonists include agents which increase Smad6 expression, binding or activity.

5 When administered, the therapeutic compositions of the present invention are administered in pharmaceutically acceptable preparations. Such preparations may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives, compatible carriers, supplementary immune potentiating agents such as adjuvants and cytokines and optionally other therapeutic agents.

10 The therapeutics of the invention can be administered by any conventional route, including injection or by gradual infusion over time. The administration may, for example, be oral, intravenous, intraperitoneal, intramuscular, intracavity, subcutaneous, or transdermal. When antibodies are used therapeutically, a preferred route of administration is by pulmonary aerosol. Techniques for preparing aerosol delivery systems containing antibodies are well known to those of skill in the art. Generally, such systems should utilize components which will not significantly impair the biological properties of the antibodies, such as the paratope binding capacity (see, for example, Sciarra and Cutie, "Aerosols," in Remington's Pharmaceutical Sciences, 18th edition, 1990, pp 1694-1712; incorporated by reference). Those of skill in the art can readily determine the various parameters and conditions for producing antibody aerosols

15 without resort to undue experimentation. When using antisense preparations of the invention, slow intravenous administration is preferred.

20 Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as,

25 for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like.

30 The preparations of the invention are administered in effective amounts. An effective amount is that amount of a pharmaceutical preparation that alone, or together with further doses, produces the desired response. For example, in the case of treating cancer, the desired response

is inhibiting the progression of the cancer. In the case of treating ossification of the ligamentum flavum, the desired response is inhibiting the progression of the ossification. This may involve only slowing the progression of the disease temporarily, although more preferably, it involves halting the progression of the disease permanently. This can be monitored by routine methods or
5 can be monitored according to diagnostic methods of the invention discussed herein.

The invention also contemplates gene therapy. The procedure for performing *ex vivo* gene therapy is outlined in U.S. Patent 5,399,346 and in exhibits submitted in the file history of that patent, all of which are publicly available documents. In general, it involves introduction *in vitro* of a functional copy of a gene into a cell(s) of a subject which contains a defective copy of
10 the gene, and returning the genetically engineered cell(s) to the subject. The functional copy of the gene is under operable control of regulatory elements which permit expression of the gene in the genetically engineered cell(s). Numerous transfection and transduction techniques as well as appropriate expression vectors are well known to those of ordinary skill in the art, some of which are described in PCT application WO95/00654. *In vivo* gene therapy using vectors such as
15 adenovirus, retroviruses, herpes virus, and targeted liposomes also is contemplated according to the invention.

The invention further provides efficient methods of identifying pharmacological agents or lead compounds for agents active at the level of a Smad6 or Smad6 fragment modulatable cellular function. In particular, such functions include TGF- β , activin and BMP signal
20 transduction and formation of a TGF- β superfamily receptor-Smad6 protein complex. Generally, the screening methods involve assaying for compounds which interfere with a Smad6 activity such as TGF- β receptor-Smad6 binding, etc. Such methods are adaptable to automated, high throughput screening of compounds. The target therapeutic indications for pharmacological agents detected by the screening methods are limited only in that the target cellular function be
25 subject to modulation by alteration of the formation of a complex comprising a Smad6 polypeptide or fragment thereof and one or more natural Smad6 intracellular binding targets, such as TGF- β receptor. Target indications include cellular processes modulated by TGF- β , activin and BMP signal transduction following receptor-ligand binding.

A wide variety of assays for pharmacological agents are provided, including, labeled *in*
30 *vitro* protein-protein binding assays, electrophoretic mobility shift assays, immunoassays, cell-based assays such as two- or three-hybrid screens, expression assays, etc. For example, three-hybrid screens are used to rapidly examine the effect of transfected nucleic acids on the intracellular binding of Smad6 or Smad6 fragments to specific intracellular targets. The

transfected nucleic acids can encode, for example, combinatorial peptide libraries or antisense molecules. Convenient reagents for such assays, e.g., GAL4 fusion proteins, are known in the art. An exemplary cell-based assay involves transfecting a cell with a nucleic acid encoding a Smad6 polypeptide fused to a GAL4 DNA binding domain and a nucleic acid encoding a TGF- β receptor domain which interacts with Smad6 fused to a transcription activation domain such as VP16. The cell also contains a reporter gene operably linked to a gene expression regulatory region, such as one or more GAL4 binding sites. Activation of reporter gene transcription occurs when the Smad6 and TGF- β receptor fusion polypeptides bind such that the GAL4 DNA binding domain and the VP16 transcriptional activation domain are brought into proximity to enable transcription of the reporter gene. Agents which modulate a Smad6 polypeptide mediated cell function are then detected through a change in the expression of reporter gene. Methods for determining changes in the expression of a reporter gene are known in the art.

Smad6 fragments used in the methods, when not produced by a transfected nucleic acid are added to an assay mixture as an isolated polypeptide. Smad6 polypeptides preferably are produced recombinantly, although such polypeptides may be isolated from biological extracts. Recombinantly produced Smad6 polypeptides include chimeric proteins comprising a fusion of a Smad6 protein with another polypeptide, e.g., a polypeptide capable of providing or enhancing protein-protein binding, sequence specific nucleic acid binding (such as GAL4), enhancing stability of the Smad6 polypeptide under assay conditions, or providing a detectable moiety, such as green fluorescent protein or Flag epitope as provided in the examples below.

The assay mixture is comprised of a natural intracellular Smad6 binding target such as a TGF- β receptor or fragment thereof capable of interacting with Smad6. While natural Smad6 binding targets may be used, it is frequently preferred to use portions (e.g., peptides or nucleic acid fragments) or analogs (i.e., agents which mimic the Smad6 binding properties of the natural binding target for purposes of the assay) of the Smad6 binding target so long as the portion or analog provides binding affinity and avidity to the Smad6 fragment measurable in the assay.

The assay mixture also comprises a candidate pharmacological agent. Typically, a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a different response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e., at zero concentration of agent or at a concentration of agent below the limits of assay detection. Candidate agents encompass numerous chemical classes, although typically they are organic compounds. Preferably, the candidate pharmacological agents are small organic compounds, i.e., those having a molecular weight of more than 50 yet less than

about 2500, preferably less than about 1000 and, more preferably, less than about 500. Candidate agents comprise functional chemical groups necessary for structural interactions with polypeptides and/or nucleic acids, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups and more preferably at 5 least three of the functional chemical groups. The candidate agents can comprise cyclic carbon or heterocyclic structure and/or aromatic or polyaromatic structures substituted with one or more of the above-identified functional groups. Candidate agents also can be biomolecules such as peptides, saccharides, fatty acids, sterols, isoprenoids, purines, pyrimidines, derivatives or structural analogs of the above, or combinations thereof and the like. Where the agent is a 10 nucleic acid, the agent typically is a DNA or RNA molecule, although modified nucleic acids as defined herein are also contemplated.

Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including 15 expression of randomized oligonucleotides, synthetic organic combinatorial libraries, phage display libraries of random peptides, and the like. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural and synthetically produced libraries and compounds can be readily be modified through conventional chemical, physical, and biochemical means. Further, known 20 pharmacological agents may be subjected to directed or random chemical modifications such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs of the agents.

A variety of other reagents also can be included in the mixture. These include reagents such as salts, buffers, neutral proteins (e.g., albumin), detergents, etc. which may be used to 25 facilitate optimal protein-protein and/or protein-nucleic acid binding. Such a reagent may also reduce non-specific or background interactions of the reaction components. Other reagents that improve the efficiency of the assay such as protease, inhibitors, nucleasc inhibitors, antimicrobial agents, and the like may also be used.

The mixture of the foregoing assay materials is incubated under conditions whereby, but 30 for the presence of the candidate pharmacological agent, the Smad6 polypeptide specifically binds the cellular binding target, a portion thereof or analog thereof. The order of addition of components, incubation temperature, time of incubation, and other perimeters of the assay may be readily determined. Such experimentation merely involves optimization of the assay

parameters, not the fundamental composition of the assay. Incubation temperatures typically are between 4 °C and 40 °C. Incubation times preferably are minimized to facilitate rapid, high throughput screening, and typically are between 0.1 and 10 hours.

After incubation, the presence or absence of specific binding between the Smad6 polypeptide and one or more binding targets is detected by any convenient method available to the user. For cell free binding type assays, a separation step is often used to separate bound from unbound components. The separation step may be accomplished in a variety of ways. Conveniently, at least one of the components is immobilized on a solid substrate, from which the unbound components may be easily separated. The solid substrate can be made of a wide variety of materials and in a wide variety of shapes, e.g., microtiter plate, microbead, dipstick, resin particle, etc. The substrate preferably is chosen to maximum signal to noise ratios, primarily to minimize background binding, as well as for ease of separation and cost.

Separation may be effected for example, by removing a bead or dipstick from a reservoir, emptying or diluting a reservoir such as a microtiter plate well, rinsing a bead, particle, chromatographic column or filter with a wash solution or solvent. The separation step preferably includes multiple rinses or washes. For example, when the solid substrate is a microtiter plate, the wells may be washed several times with a washing solution, which typically includes those components of the incubation mixture that do not participate in specific bindings such as salts, buffer, detergent, non-specific protein, etc. Where the solid substrate is a magnetic bead, the beads may be washed one or more times with a washing solution and isolated using a magnet.

Detection may be effected in any convenient way for cell-based assays such as two- or three-hybrid screens. The transcript resulting from a reporter gene transcription assay of Smad6 polypeptide interacting with a target molecule typically encodes a directly or indirectly detectable product, e.g., β-galactosidase activity, luciferase activity, and the like. For cell free binding assays, one of the components usually comprises, or is coupled to, a detectable label. A wide variety of labels can be used, such as those that provide direct detection (e.g., radioactivity, luminescence, optical or electron density, etc.) or indirect detection (e.g., epitope tag such as the FLAG epitope, enzymic tag such as horseradish peroxidase, etc.). The label may be bound to a Smad6 binding partner, or incorporated into the structure of the binding partner.

A variety of methods may be used to detect the label, depending on the nature of the label and other assay components. For example, the label may be detected while bound to the solid substrate or subsequent to separation from the solid substrate. Labels may be directly detected through optical or electron density radioactive emissions, nonradiative energy transfers, etc. or

indirectly detected with antibody conjugates, streptavidin-biotin conjugates, etc. Methods for detecting the labels are well known in the art.

The invention provides Smad6-specific binding agents, methods of identifying and making such agents, and their use in diagnosis, therapy and pharmaceutical development. For example, Smad6-specific pharmacological agents are useful in a variety of diagnostic and therapeutic applications, especially where disease or disease prognosis is associated with improper utilization of a pathway involving Smad6, e.g., TGF- β induced phosphorylation of Smad1 or Smad2, TGF- β superfamily receptor-Smad6 complex formation, etc. Novel Smad6-specific binding agents include Smad6-specific antibodies and other natural intracellular binding agents identified with assays such as two hybrid screens, and non-natural intracellular binding agents identified in screens of chemical libraries and the like.

In general, the specificity of Smad6 binding to a binding agent is shown by binding equilibrium constants. Targets which are capable of selectively binding a Smad6 polypeptide preferably have binding equilibrium constants of at least about 10^7 M^{-1} , more preferably at least about 10^8 M^{-1} , and most preferably at least about 10^9 M^{-1} . The wide variety of cell based and cell free assays may be used to demonstrate Smad6-specific binding. Cell based assays include one, two and three hybrid screens, assays in which Smad6-mediated transcription is inhibited or increased, etc. Cell free assays include Smad6-protein binding assays, immunoassays, etc. Other assays useful for screening agents which bind Smad6 polypeptides include fluorescence resonance energy transfer (FRET), and electrophoretic mobility shift analysis (EMSA).

Various techniques may be employed for introducing nucleic acids of the invention into cells, depending on whether the nucleic acids are introduced *in vitro* or *in vivo* in a host. Such techniques include transfection of nucleic acid-CaPO₄ precipitates, transfection of nucleic acids associated with DEAE, transfection with a retrovirus including the nucleic acid of interest, liposome mediated transfection, and the like. For certain uses, it is preferred to target the nucleic acid to particular cells. In such instances, a vehicle used for delivering a nucleic acid of the invention into a cell (e.g., a retrovirus, or other virus; a liposome) can have a targeting molecule attached thereto. For example, a molecule such as an antibody specific for a surface membrane protein on the target cell or a ligand for a receptor on the target cell can be bound to or incorporated within the nucleic acid delivery vehicle. For example, where liposomes are employed to deliver the nucleic acids of the invention, proteins which bind to a surface membrane protein associated with endocytosis may be incorporated into the liposome formulation for targeting and/or to facilitate uptake. Such proteins include capsid proteins or

fragments thereof tropic for a particular cell type, antibodies for proteins which undergo internalization in cycling, proteins that target intracellular localization and enhance intracellular half life, and the like. Polymeric delivery systems also have been used successfully to deliver nucleic acids into cells, as is known by those skilled in the art. Such systems even permit oral
5 delivery of nucleic acids.

Examples

10 **Methods**

Cloning of mouse Smad6 and Northern blot

A mouse lung cDNA library (Stratagene) was screened with an EST clone (clone ID 429356) as a probe. One of the clones contained the entire coding region of the mouse Smad6 and was sequenced using an ALFred sequencer (Pharmacia Biotech) and a Sequenase 15 sequencing kit (USB). Sequence analysis was done with DNASTAR (DNASTAR, Inc.). Human and mouse tissue blots (Clontech) were probed with the EST clone.

Plasmids

Mammalian expression vectors with an amino-terminal tag (FLAG or Myc) were 20 constructed by inserting oligonucleotides encoding the epitope-tag sequence into pcDNA3 (Invitrogen). The coding region of the mouse Smad6 was amplified by PCR and subcloned into Myc-pcDNA3 or FLAG-pcDNA3. The integrity of the products were confirmed by sequencing. Smad1, Smad2, Smad3 and Smad4 expression plasmids were constructed in a similar manner.

25

Affinity cross-linking and immunoprecipitation

Iodination of TGF- β 1 (R&D Systems), activin A (gift of Y. Eto), and OP1/BMP-7 (gift of T.K. Sampath) and the following immunoprecipitation were performed as described (Okadome et al., *J. Biol. Chem.* 271:21687-21690, 1996).

30

Western blot and *in vivo* phosphorylation

COS-7 cells were transiently transfected using DMRIE-C (Gibco/BRL). [³²P]orthophosphate- or [³⁵S]methionine/cysteine-labeling and immunoprecipitation were done as

described by Nakao et al. (*J. Biol. Chem.* 272:2896-2900, 1997). For Western blot of the immunoprecipitated proteins, tagged proteins were detected by chemiluminescence (ECL, Amersham).

5 Luciferase assays

Mink R mutant cells were transiently transfected with an appropriate combination of a reporter, expression plasmids, and pcDNA3 using Tfx-50 (Promega). Total amounts of transfected DNA were the same in each experiment, and values were normalized using sea pansy luciferase activity under the control of the thymidine kinase promoter (pRL-TK, Toyo

10 Ink).

Cell cultures

C1C12 cells, F9 cells, and ST2 cells were obtained from Riken Cell Bank (Tsukuba, Japan). 10T1/2 cells were from American Type Culture Collection (Bethesda, MD, USA).

15 C1C12 cells and 10T1/2 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% FBS, 100 units of penicillin and 50 µg of streptomycin per ml. F9 cells were cultured in DMEM with 15% FBS and the antibiotics, and ST2 cells were cultured in RPMI1640 with 10% FBS and the antibiotics. The cells were kept in 5% CO₂ humid atmosphere at 37°C.

20

Poly(A)⁺ RNA isolation and Northern blotting

Poly(A⁺) RNA was obtained using Oligotex dT-30 Super latex beads (Takara Shuzo Co., Ltd.) according to the manufacturer's method. Poly(A⁺) RNA (3 µg) from cells treated with BMP-2 (300 ng/ml), BMP-7/OP-1(300 ng/ml), or TGF-β1 (25 ng/ml) for various time periods were electrophoresed in 1% gel in the presence of 2.2 M formaldehyde gels and blotted to Hybond N membranes (Amersham). The complete coding region of mouse Smad6 cDNA was labeled by [α -³²P]dCTP using Random Primer Labeling Kit (Takara Shuzo Co., Ltd.). Hybridization was performed in a solution containing 5 x SSC, 1% SDS, 5 x Denbandt's solution and 10 µg/ml salmon sperm DNA at 65°C with 2 x SSC, 1% SDS for 20 min. twice, 0.5 x SSC, 1% SDS for 30 min. 0.2 x SSC, 1% SDS for 10 min. The filters were stripped by boiled distilled water containing 0.1% SDS and rehybridized.

Example 1: Identification of Smad6 and determination of its expression

In search of new members of the Smad family, several expressed-sequence tag (EST) sequences that are not ascribed to the five mammalian Smads characterized previously (Massagué et al., 1997) were identified. We screened a mouse lung cDNA library using one of the EST clones (clone ID 429356) as a probe and identified overlapping clones encoding the 5 same protein of 495 amino acids with a predicted molecular weight of 53.7 kDa (Fig. 1a, SEQ ID NO:2; GenBank accession number AF010133). Identical residues are boxed. The C-terminal amino acid sequence of the protein was almost identical with the entire protein sequence of a GenBank clone deposited as the human Smad6 (235 amino acids, accession number: U59914). It thus was concluded that our clone is the full-length mouse Smad6.

10 Chromosomal localization of the human Smad6 (JV15-1) has been reported (Riggins et al., *Nature Genet.* 13:347-349, 1996). Except for the human Smad6, all of the Smads, including *Drosophila* and *C. elegans* Smads, comprise conserved N-terminal and C-terminal regions (MH1 and MH2, respectively) separated by a proline-rich linker region of variable length and sequence, although Smad4 has a unique insert in its MH2 region (Massagué, et al., 1997). The 15 C-terminal one-third of Smad6 shares the conserved sequence with the MH2 regions of the other Smads, whereas its N-terminal region shows a striking difference from the conserved MH1 sequence (Fig. 1a), suggesting a novel function of this molecule.

Northern blot analysis of various human and mouse tissues, using the human EST clone 429356 as a probe, revealed relatively ubiquitous expression of the mRNA species of 20 3.0 kb with the highest expression in lung (Fig. 1b; human (left) and mouse (right)).

Example 2: Receptor binding of Smad6

Members of the TGF- β superfamily exert their diverse effects through binding to two types of receptors with serine-threonine kinase activity (Yingling et al., *Biochim. Biophys. Acta* 1242:115-136, 1995). The ligand first binds to the type II receptor, which consequently activates the type I receptor by direct phosphorylation. The activated type I receptor then phosphorylates ligand-specific Smads such as Smad1, Smad2, and Smad3 (Massagué, et al., 1997; Zhang et al., *Nature* 383:168-172, 1996; Lagna et al., *Nature* 383:832-836, 1996; Macías-Silva et al., *Cell* 87:1215-1224, 1996). The association of Smad2 with T β R-I requires 25 activation of T β R-I by the type II receptor (T β R-II) (Macías-Silva et al., 1996). Smad2, however, interacts with T β R-I only transiently under physiological conditions, since Smad2 is released from T β R-I after phosphorylation by the receptor. The 30 interaction of Smad2 with the T β R-I has thus been observed only when the kinase-defective

form of T β R-I is used (Macías-Silva et al., 1996). It should be noted that Smad4 does not associate the receptors (Zhang et al., 1996).

The interaction of Smad6 with the type I receptors was examined in affinity cross-linking assays. COS-7 cells were transfected with FLAG-tagged Smad6 (F-Smad6) or FLAG-tagged Smad2 (F-Smad2) in combination with the wild type (wt) or kinase-defective (KR) HA-tagged T β R-I and hexahistidine-tagged T β R-II. Cells were affinity labeled with 125 I-TGF- β 1 and lysates were immunoprecipitated with anti-IIA antibody or anti-FLAG M2 antibody. Immune complexes were subjected to SDS-PAGE and autoradiography. Smad6 bound to both wild type and kinase-defective T β R-I depending on the kinase activity of T β R-II. In contrast, Smad2 bound to kinase-defective T β R-I but not to the wild type T β R-I. Smad6 bound to the TGF- β receptor complexes as revealed by the coprecipitation of the receptor complexes with Smad6 (Fig. 2a). Similarly to Smad2, the binding of Smad6 to T β R-I required the kinase activity of T β R-II (Fig. 2a). Smad6, however, stably bound to the wild type T β R-I.

Similar results were obtained with the activin type IB receptor (ActR-IB) using 125 I-activin A (Fig. 2B) and the BMP type IB receptor (BMPR-IB) using 125 I-OP-1/BMP-7 (Fig. 2C) in which Smad6 bound to both wild type and kinase-defective type I receptors. These results suggest that Smad6 binds to the type I receptors in a ligand-dependent manner but exerts a role different from that of the other Smads.

20 Example 3: Effect of Smad6 on phosphorylation of Smads

Smad2 is phosphorylated at its carboxy-terminal end by activated T β R-I (Macías-Silva et al., 1996). The phosphorylation is essential to the following downstream signaling events that culminate in transcriptional activation of the target genes, since disruption of the phosphorylation sites abrogated TGF- β -induced responses (Macías-Silva et al., 1996). Thus the effect of Smad6 on the phosphorylation of Smad2 was examined (Fig. 3). COS-7 cells were transiently transfected with constitutively active (TD) T β R-I, FLAG-Smad2 (F-Smad2), and/or Myc-Smad6 (M-Smad6). Cells were labeled with [32 P]orthophosphate and lysates were subjected to immunoprecipitation with anti-Myc antibody. Phosphorylated Smad6 was detected by SDS-PAGE and autoradiography. Doublet bands of phosphorylated Smad6 were detected. Cell lysates also were immunoprecipitated with anti-FLAG antibody to detect Smad2 phosphorylation. Expression levels of Smad6 (panel A), Smad2 and T β R-I (TD) (panel B) were monitored by labeling of the cells with [35 S)methionine/cysteine.

Neither T β R-I (TD) or FLAG-Smad2 affected the phosphorylation of Smad6.

Phosphorylation of Smad2 induced by constitutively active T β R-I was suppressed by Smad6 (39% reduction as normalized for the 35 S-labeled band), whereas Smad2 did not affect constitutive phosphorylation of Smad6 (Fig. 3A, B).

Smad3 and Smad2 share 91% identity in their amino acid sequences and are 5 independently shown to mediate TGF- β signals (Eppert et al. *Cell* 86:543-552, 1996; Zhang et al., 1996), although functional differences of the two molecules are still unknown. A similar experiment as above was done with Smad3. Smad6 rather enhanced receptor-induced phosphorylation of Smad3 (Fig. 3C), suggesting differential effects of Smad6 to these closely related molecules.

10 Next, the effect of Smad6 on Smad1 phosphorylation was studied (Fig. 3D). Smad1 was phosphorylated by the constitutively active BMP type IA receptor (BMPR-IA) as well as BMPR-IB. Smad6 efficiently inhibited phosphorylation induced by the latter (60% reduction) but not by the former. These results suggest that Smad6 acts as an inhibitor to certain members of the Smad family.

15

Example 4: Effect of Smad6 on Smad complex formation

Smad2 heteromerizes with Smad4 upon phosphorylation by T β R-I (Lagna et al., 1996). It was recently shown that TGF- β also induces association of Smad2 and Smad3 (Nakao et al., *EMBO J.* 16:5353-5362, 1997). The effect of Smad6 on the heteromerization of these Smads 20 was examined (Fig. 4). COS-7 cells were transfected with the indicated combination of plasmids and subjected to immunoprecipitation followed by Western blot detection. Expression levels of Smad2 (bottom), Smad4 (middle), and Smad6 (middle) were monitored. Note that Smad6 did not interact with Smad2 under these conditions (top).

Smad2 formed a complex with Smad4 in the presence of constitutively active T β R-I as 25 shown by coprecipitation of Smad4 with Smad2. The complex formation was abrogated by Smad6 (Fig. 4A, top panel). T β R-I-induced interaction of Smad3 and Smad4, however, was not affected by Smad6 (Fig. 4B), as Smad4 coprecipitated with Smad3 both in the presence and absence of Smad6 (top). This is consistent with the result that Smad6 does not inhibit Smad3 phosphorylation (Fig. 3C). Furthermore, heteromerization of Smad2 and Smad3 was 30 inhibited by Smad6 (Fig. 4C), suggesting that phosphorylation of both proteins is necessary for this interaction. These results suggest that Smad6 specifically interferes with the activation of Smad2 in TGF- β signaling.

Example 5: Effect of Smad6 on TGF- β signaling

The role of Smad6 in TGF- β signaling was tested, as assessed by luciferase reporter gene assays. P3TP-Lux, a sensitive reporter for TGF- β , was used in R mutant mink cells deficient in T β R-I (Fig. 5). Wild type T β R-I restored TGF- β response in these cells. Mink R 5 mutant cells deficient in T β R-I were transfected with p3TP-Lux reporter, T β R-I, and increasing amounts (μ g) of Smad6 DNA. Cells were treated with (closed bars) or without (open bars) 5 ng/ml TGF- β 1 for 24 h. Smad6 suppressed the activation of the reporter gene in a dose-dependent manner (Fig. 5a). Transcriptional activation by constitutively active T β R-I was suppressed as well (Fig. 5b).

10 Cyclin A expression is necessary for cell cycle progression and is suppressed by TGF- β (Feng et al., *J. Biol. Chem.* 270:4237-24245, 1995). A cyclin A luciferase reporter, pCAL2, was used to examine the effect of Smad6 on TGF- β signaling. T β R-I (constitutively active) downregulated cyclin A luciferase activity, but increasing amounts of Smad6 counteracted the effects of T β R-I in the cyclin A luciferase assay (Fig. 5c). These results 15 indicate that Smad6 interfered with TGF- β signals in two distinct responses.

Example 6: Regulation of Smad6 expression by TGF- β 1 and BMPs

To determine the mechanisms by which the expression of Smad6 is controlled, the effect 20 of TGF- β and other family members on Smad6 mRNA expression was examined. To determine the effect of BMP-2, BMP-2 was added at 300 ng/ml to the culture medium of several BMP-2-responsive cell lines: F9, C3H10T $\frac{1}{2}$, ST2 and C2C12. After 6 hours, poly A $^+$ mRNA was isolated from the cells as described above. Samples of mRNA were electrophoresed, blotted and probed with 32 P-labeled Smad6 coding region. The results of the Northern blot are shown in Fig. 6A. Expression of Smad6 was induced in all of the BMP-2 responsive cell lines after BMP treatment.

25 To determine the effect of OP-1/BMP-7, the expression of Smad6 mRNA in C2C12 myoblasts after stimulation with 300 ng/ml OP-1/BMP-7 was tested. Poly A $^+$ mRNA was isolated at the indicated times following OP-1/BMP-7 stimulation. As shown in Fig. 6B, Smad6 expression was induced by OP-1/BMP-7 at 6 hours after stimulation, and remained induced up to at least 48 hours after stimulation, the duration of the experiment.

30 To determine the effect of TGF- β 1, the expression of Smad6 mRNA in C2C12 myoblasts after stimulation with 25 ng/ml TGF- β 1 was tested. Poly A $^+$ mRNA was isolated at the indicated times following TGF- β 1 stimulation. As shown in Fig. 6C, Smad6 expression was induced by TGF- β 1 at 1 hour after stimulation, but decreased thereafter. After 12 hours, the expression of

Smad6 mRNA was below the basal level of expression.

In summary, the BMPs tested (BMP-2 and BMP-7/OP-1) induced the expression of Smad6 mRNA. In contrast, TGF- β 1 initially induced the expression of Smad6, but Smad6 levels subsequently decreased to below basal levels. Thus different members of the TGF superfamily 5 exert opposing effects on the expression of Smad6.

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described 10 herein. Such equivalents are intended to be encompassed by the following claims.

All references disclosed herein are incorporated by reference in their entirety.

A Sequence Listing is presented followed by what is claimed:

- 40 -

SEQUENCE LISTING

(1) GENERAL INFORMATION

5

(i) APPLICANT:

- (A) NAME: LUDWIG INSTITUTE FOR CANCER RESEARCH
- (B) STREET: 1345 AVENUE OF THE AMERICAS
- (C) CITY: NEW YORK
- (D) STATE: NEW YORK
- 10 (E) COUNTRY: UNITED STATES OF AMERICA
- (F) POSTAL CODE: 10105

10

(i) APPLICANT:

- (A) NAME: JAPANESE FOUNDATION FOR CANCER RESEARCH
- 15 (B) STREET: 1-37-1 KAMI-IKEBUKURO, 1-CHOME, TOSHIMA-KU
- (C) CITY: TOKYO 170
- (E) COUNTRY: JAPAN

15

(ii) TITLE OF THE INVENTION: SMAD6 AND USES THEREOF

20

(iii) NUMBER OF SEQUENCES: 10

(iv) CORRESPONDENCE ADDRESS:

- 25 (A) ADDRESSEE: Wolf, Greenfield & Sacks, P.C.
- (B) STREET: 600 Atlantic Avenue
- (C) CITY: Boston
- (D) STATE: MA
- (E) COUNTRY: U.S.A.
- 30 (F) ZIP: 02210-2211

30

(v) COMPUTER READABLE FORM:

- 41 -

- (A) MEDIUM TYPE: Diskette
- (B) COMPUTER: IBM Compatible
- (C) OPERATING SYSTEM: DOS
- (D) SOFTWARE: FastSEQ for Windows Version 2.0

5

(vi) CURRENT APPLICATION DATA:

- (A) APPLICATION NUMBER:
- (B) FILING DATE:
- (C) CLASSIFICATION:

10

(vii) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: 60/049,990
- (B) FILING DATE: 13-JUN-1997

15

- (A) APPLICATION NUMBER: 60/053,040
- (B) FILING DATE: 18-JUL-1997

- (A) APPLICATION NUMBER: 60/066,173
- (B) FILING DATE: 18-NOV-1997

20

(viii) ATTORNEY/AGENT INFORMATION:

- (A) NAME: Van Amsterdam, John R.
- (B) REGISTRATION NUMBER: 40,212
- (C) REFERENCE/DOCKET NUMBER: L0461/7038WO

25

(ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: 617-720-3500
- (B) TELEFAX: 617-720-2441
- (C) TELEX:

30

(2) INFORMATION FOR SEQ ID NO:1:

- 42 -

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2534 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- 5 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- 10 (A) NAME/KEY: Coding Sequence
(B) LOCATION: 751...2235
(D) OTHER INFORMATION:

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CCCCTCGAGG TCGACGGTAT CGATAAGCTT GATATCGAAT TCCTTTTTT TTATGGCTTC	60
CACTCATGTG TTGACACCCG CGITCAGGAG AGACTTGCC CAAGTGCACC GAGCGCCCGG	120
GACCTGAGAC GGAATTGCTT TTCGTGCGTG CAAAATCCAA GCATTTGAG TTTTGTGAGG	180
20 GACCTTTTC TTGCTTTGCT TTTATTTCTA TTTTTATTTC GTTGCAGGGA TATGGGAGTT	240
ATCCACAAGC CTTAGTTTCG GATCCTGCAG GGAAAGCCCA TGTAGCATAG CTTGGCTTT	300
GAAGGCAGAG TTGIGCAGAC ACATTTGGGG GCACCGACGCA AGCGCTTTGT GCTCGTGTAC	360
CAGCCGCGCA ACTTTGAAG GCTCGCCGGC CCATGCAGGG TGTCTCTAGC ATCGTTTCGC	420
TGGTGGCTTC CCTAAGGCTC CAAAGCAGCT GGAGTTGAGC GGTCCCCGCC CATCGTGATC	480
25 CATGTAGCCC GCTGGTCCCT CGCGGACTGA GGCTCAACAC GCGCGTGTTC CCGGCCCCGGC	540
CCGGCCCCGGC TTGGCCCCGGC GCGAGCTCCC TCATGTTGCA GCCCTGCGGT GCCCCCTTCGA	600
CGACAGGCTG TTGCGCGGTC TGACACGGCGC CCCGCGGCAG AGCTTCATGT GGGGCTGGGG	660
CCGCTCAGCC GGCGCCTCGT TGAGGSAACG GACCCCCGGT AACCGGAGAC CGCCTCCCC	720
CCCACCAHHH MAGGCGCCAA AGGGTATCGT ATG TTC AGG TCT AAA CGT TCG GGG	774
30 Met Phe Arg Ser Lys Arg Ser Gly	

- 43 -

CTG GTG CGA CGA CTT TGG CGA AGT CGT GTG GTC CCT GAT CGG GAG GAA
 Leu Val Arg Arg Leu Trp Arg Ser Arg Val Val Pro Asp Arg Glu Glu
 10 15 20

5 GGC AGC GGC GGC GGC GGT GGT GTC GAC GAG GAT GGG AGC CTG GGC AGC
 Gly Ser Gly Gly Gly Val Asp Glu Asp Gly Ser Leu Gly Ser
 25 30 35 40

10 CGA GCT GAG CCT GCC CCG CGG GCA CGA GAG GGC GGA GGC TGC AGC CGC
 Arg Ala Glu Pro Ala Pro Arg Ala Arg Glu Gly Gly Cys Ser Arg
 45 50 55

15 TCC GAA GTC CGC TCG GTA GCC CCG CGG CGG CCC CGG GAC GCG GTG GGA
 Ser Glu Val Arg Ser Val Ala Pro Arg Arg Pro Arg Asp Ala Val Gly
 60 65 70

20 CCG CGA GGC GCC GCG ATC GCG GGC AGG CGC CGG CGC ACA GCA GGG GGC CTC
 Pro Arg Gly Ala Ala Ile Ala Gly Arg Arg Arg Arg Thr Gly Gly Leu
 75 80 85

25 CCG AGG CCC GTG TCG GAG TCG GGG GCC GGG GCT GGG GGC TCC CCG CTG
 Pro Arg Pro Val Ser Glu Ser Gly Ala Gly Ala Gly Gly Ser Pro Leu
 90 95 100

30 GAT GTG GCG GAG CCT GGA GGC CCA GGC TGG CTG CCT GAG AGT GAC TGC
 Asp Val Ala Glu Pro Gly Pro Gly Trp Leu Pro Glu Ser Asp Cys
 105 110 115 120

35 GAG ACG GTG ACC TGC TGT CTC TTC TCC GAA CGG GAC GCA GCA GGC GCG
 Glu Thr Val Thr Cys Cys Leu Phe Ser Glu Arg Asp Ala Ala Gly Ala
 125 130 135

- 44 -

CCC CGG GAC TCT GGC GAT CCC CAA GCC AGA CAG TCC CCG GAG CCG GAG 1206
 Pro Arg Asp Ser Gly Asp Pro Gln Ala Arg Gln Ser Pro Glu Pro Glu
 140 145 150

5 GAG GGC GGC GGG CCT CGG AGT CGC GAA GCC CGC TCG CGA CTG CTG CTT 1254
 Glu Gly Gly Pro Arg Ser Arg Glu Ala Arg Ser Arg Leu Leu Leu
 155 160 165

10 CTG GAG CAG GAG CTC AAG ACG GTC ACG TAC TCG CTG CTC AAG AGG CTC 1302
 Leu Glu Gln Glu Leu Lys Thr Val Thr Tyr Ser Leu Leu Lys Arg Leu
 170 175 180

15 AAG GAG CGT TCG CTG GAC ACG CTG TTG GAG GCT GTG GAG TCC CGA GGC 1350
 Lys Glu Arg Ser Leu Asp Thr Leu Leu Glu Ala Val Glu Ser Arg Gly
 185 190 195 200

20 GGC GTA CCG GGC GGC TGC GTG CTG GTG CCG CGC GCC GAC CTC CGC TTG 1398
 Gly Val Pro Gly Gly Cys Val Leu Val Pro Arg Ala Asp Leu Arg Leu
 205 210 215

25 GGC GGC CAG CCC GCG CCA CCG CAG CTG CTG CTC GGC CGC CTC TTC CGC 1446
 Gly Gly Gln Pro Ala Pro Pro Gln Leu Leu Gly Arg Leu Phe Arg
 220 225 230

30 TGG CCA GAC CTG CAG CAC GCA GTG GAG CTG AAA CCC CTG TGC GGC TGC 1494
 Trp Pro Asp Leu Gln His Ala Val Glu Leu Lys Pro Leu Cys Gly Cys
 235 240 245

CAC AGC TTT ACC GCC GCC GAC GGG CCC ACG GTG TGT TGC AAC CCC 1542
 His Ser Phe Thr Ala Ala Asp Gly Pro Thr Val Cys Cys Asn Pro
 250 255 260

- 45 -

TAC CAC TTC AGC CGG CTC TGC GGG CCA GAA TCA CCG CCG CCC CCC TAT 1590
 Tyr His Phe Ser Arg Leu Cys Gly Pro Glu Ser Pro Pro Pro Pro Tyr
 265 270 275 280

5 TCT CGG CTG TCT CCT GAC CAG TAC AAG CCA CTG GAT CTG TCC GAT 1638
 Ser Arg Leu Ser Pro Pro Asp Gln Tyr Lys Pro Leu Asp Leu Ser Asp
 285 290 295

10 TCT ACA TTG TCT TAC ACT GAA ACC GAG GCC ACC AAC TCC CTC ATC ACT 1686
 Ser Thr Leu Ser Tyr Thr Glu Thr Ala Thr Asn Ser Leu Ile Thr
 300 305 310

15 GCT CCG GGT GAA TTC TCA GAT GCC AGC ATG TCT CCG GAT GCC ACC AAG 1734
 Ala Pro Gly Glu Phe Ser Asp Ala Ser Met Ser Pro Asp Ala Thr Lys
 315 320 325

20 CCG AGC CAC TGG TGC AGC GTG GCG TAC TGG GAG CAC CGG ACA CGC GTG 1782
 Pro Ser His Trp Cys Ser Val Ala Tyr Trp Glu His Arg Thr Arg Val
 330 335 340

25 GGC CGC CTC TAT GCG GTG TAC GAC CAG GCT GTC AGC ATT TTC TAC GAC 1830
 Gly Arg Leu Tyr Ala Val Tyr Asp Gln Ala Val Ser Ile Phe Tyr Asp
 345 350 355 360

30 CTA CCT CAG GGC AGC GGC TTC TGC CTG GGC CAG CTC AAC CTG GAG CAG 1878
 Leu Pro Gln Gly Ser Gly Phe Cys Leu Gly Gln Leu Asn Leu Glu Gln
 365 370 375

35 CGC AGT GAG TCG GTG CGG CGC ACG CGC AGC AAG ATC GGT TTT GGC ATA 1926
 Arg Ser Glu Ser Val Arg Arg Thr Arg Ser Lys Ile Gly Phe Gly Ile
 380 385 390

- 46 -

CTG CTC AGC AAG GAG CCA GAC GGC GTG TGG GCC TAC AAC CGG GGC GAG 1974
 Leu Leu Ser Lys Glu Pro Asp Gly Val Trp Ala Tyr Asn Arg Gly Glu
 395 400 405

5 CAC CCC ATC TTC GTC AAC TCC CCG ACG CTG GAT GCG CCC GGA GGC CGC 2022
 His Pro Ile Phe Val Asn Ser Pro Thr Leu Asp Ala Pro Gly Gly Arg
 410 415 420

GCC CTG GTC GTG CGC AAG GTG CCA CCG GGT TAC TCC ATC AAG GTG TTC 2070
 10 Ala Leu Val Val Arg Lys Val Pro Pro Gly Tyr Ser Ile Lys Val Phe
 425 430 435 440

GAC TTT GAG CGC TCA GGG CTG CTG CAG CAC GCA GAC GCC GCT CAC GGC 2118
 Asp Phe Glu Arg Ser Gly Leu Leu Gln His Ala Asp Ala Ala His Gly
 15 445 450 455

CCC TAC GAC CCG CAC AGT GTG CGC ATC AGC TTC GCC AAG GGC TGG GGA 2166
 Pro Tyr Asp Pro His Ser Val Arg Ile Ser Phe Ala Lys Gly Trp Gly
 460 465 470
 20

CCC TGC TAC TCG CGA CAG TTC ATC ACC TCC TGC CCC TGT TGG CTG GAG 2214
 Pro Cys Tyr Ser Arg Gln Phe Ile Thr Ser Cys Pro Cys Trp Leu Glu
 475 480 485

25 ATC CTA CTC AAC AAC CAC AGA TAGCAATGCG GCTGCCACTG TGCCCGAGCG TCCC 2269
 Ile Leu Leu Asn Asn His Arg
 490 495

CCAACCTCTG GGGGGCCAGC GCCCAGAGAC ACCACCCAG GGACAACCTC GCCCTCCCCC 2329
 30 CAGATATCAT CTACCTAGAT TTAAATATAAA GTTTATATAA TTATATGGAA ATATATAATTA
 TACTTGAGA ATTATGGAGT CATTCTTACA ACGTAATTAT TTATATATGG TGCAATGTGT 2389
 GTATATGGAG AAACAAGAAA GACGCACCTT GGCTTGTAAAT TCCTTCGGAA TTCCCTGCAGC 2449
 2509

CCGGGGGATC CACTAGTTCT AGAGC

2534

(2) INFORMATION FOR SEQ ID NO:2:

5 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 495 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

10

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

15

Met	Phe	Arg	Ser	Lys	Arg	Ser	Gly	Leu	Val	Arg	Arg	Leu	Trp	Arg	Ser
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

1								10					15		
---	--	--	--	--	--	--	--	----	--	--	--	--	----	--	--

Arg	Val	Val	Pro	Asp	Arg	Glu	Glu	Gly	Ser	Gly	Gly	Gly	Gly	Val
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

					20			25					30	
--	--	--	--	--	----	--	--	----	--	--	--	--	----	--

20	Asp	Glu	Asp	Gly	Ser	Leu	Gly	Ser	Arg	Ala	Glu	Pro	Ala	Pro	Arg	Ala
----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

					35			40				45			
--	--	--	--	--	----	--	--	----	--	--	--	----	--	--	--

Arg	Glu	Gly	Gly	Cys	Ser	Arg	Ser	Glu	Val	Arg	Ser	Val	Ala	Pro
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

					50			55				60		
--	--	--	--	--	----	--	--	----	--	--	--	----	--	--

Arg	Arg	Pro	Arg	Asp	Ala	Val	Gly	Pro	Arg	Gly	Ala	Ala	Ile	Ala	Gly
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

25	65				70				75				80		
----	----	--	--	--	----	--	--	--	----	--	--	--	----	--	--

Arg	Arg	Arg	Arg	Thr	Gly	Leu	Pro	Arg	Pro	Val	Ser	Glu	Ser	Gly
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

					85			90				95		
--	--	--	--	--	----	--	--	----	--	--	--	----	--	--

Ala	Gly	Ala	Gly	Gly	Ser	Pro	Leu	Asp	Val	Ala	Glu	Pro	Gly	Pro
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

					100			105				110		
--	--	--	--	--	-----	--	--	-----	--	--	--	-----	--	--

30	Gly	Trp	Leu	Pro	Glu	Ser	Asp	Cys	Glu	Thr	Val	Thr	Cys	Cys	Leu	Phe
----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

					115			120				125		
--	--	--	--	--	-----	--	--	-----	--	--	--	-----	--	--

Ser	Glu	Arg	Asp	Ala	Ala	Gly	Ala	Pro	Arg	Asp	Ser	Gly	Asp	Pro	Gln
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

- 48 -

	130	135	140
	Ala Arg Gln Ser Pro Glu Pro Glu Glu Gly Gly Pro Arg Ser Arg		
145	150	155	160
	Glu Ala Arg Ser Arg Leu Leu Leu Leu Glu Gln Glu Leu Lys Thr Val		
5	165	170	175
	Thr Tyr Ser Leu Leu Lys Arg Leu Lys Glu Arg Ser Leu Asp Thr Leu		
	180	185	190
	Leu Glu Ala Val Glu Ser Arg Gly Gly Val Pro Gly Gly Cys Val Leu		
	195	200	205
10	Val Pro Arg Ala Asp Leu Arg Leu Gly Gly Gln Pro Ala Pro Pro Gln		
	210	215	220
	Leu Leu Leu Gly Arg Leu Phe Arg Trp Pro Asp Leu Gln His Ala Val		
225	230	235	240
	Glu Leu Lys Pro Leu Cys Gly Cys His Ser Phe Thr Ala Ala Ala Asp		
15	245	250	255
	Gly Pro Thr Val Cys Cys Asn Pro Tyr His Phe Ser Arg Leu Cys Gly		
	260	265	270
	Pro Glu Ser Pro Pro Pro Tyr Ser Arg Leu Ser Pro Pro Asp Gln		
	275	280	285
20	Tyr Lys Pro Leu Asp Leu Ser Asp Ser Thr Leu Ser Tyr Thr Glu Thr		
	290	295	300
	Glu Ala Thr Asn Ser Leu Ile Thr Ala Pro Gly Glu Phe Ser Asp Ala		
305	310	315	320
	Ser Met Ser Pro Asp Ala Thr Lys Pro Ser His Trp Cys Ser Val Ala		
25	325	330	335
	Tyr Trp Glu His Arg Thr Arg Val Gly Arg Leu Tyr Ala Val Tyr Asp		
	340	345	350
	Gln Ala Val Ser Ile Phe Tyr Asp Leu Pro Gln Gly Ser Gly Phe Cys		
	355	360	365
30	Leu Gly Gln Leu Asn Leu Glu Gln Arg Ser Glu Ser Val Arg Arg Thr		
	370	375	380
	Arg Ser Lys Ile Gly Phe Gly Ile Leu Leu Ser Lys Glu Pro Asp Gly		

- 49 -

385	390	395	400
Val Trp Ala Tyr Asn Arg Gly Glu His Pro Ile Phe Val Asn Ser Pro			
405	410	415	
Thr Leu Asp Ala Pro Gly Gly Arg Ala Leu Val Val Arg Lys Val Pro			
5 420	425	430	
Pro Gly Tyr Ser Ile Lys Val Phe Asp Phe Glu Arg Ser Gly Leu Leu			
435	440	445	
Gln His Ala Asp Ala Ala His Gly Pro Tyr Asp Pro His Ser Val Arg			
450	455	460	
Ile Ser Phe Ala Lys Gly Trp Gly Pro Cys Tyr Ser Arg Gln Phe Ile			
10 465	470	475	480
Thr Ser Cys Pro Cys Trp Leu Glu Ile Leu Ile Asn Asn His Arg			
485	490	495	

15 (2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1488 base pairs
- (B) TYPE: nucleic acid
- 20 (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATGTTCAAGGT CTAAACGTTTC GGGGCTGGTG CGACGACTTT GGCGAAGTCG TGTGGTCCCT	60
GATCGGGAGG AAGGCAGCGG CGGGCGCGGT GGTGTGGACG AGGATGGGAG CCTGGGCAGC	120
CGAGCTGAGC CTGCCCGCG GGCACGAGAG GGCGGAGGCT GCAGCCGCTC CGAAGTCCGC	180
30 TCGGTAGCCC CGGGCGGCC CGGGACGCG GTGGGACCGC GAGGCCGCC GATCGCGGC	240
AGGCGCCGGC GCACAGGGGG CCTCCCCAGG CCCGTGTGG AGTCGGGGC CGGGGCTGGG	300
GGCTCCCCGC TGGATGTGGC GGAGCCTGGA GGCCCAGGCT GGCTGCCTGA GAGTGACTGC	360

- 50 -

GAGACGGTGA CCTGCTGTCT CTTCTCCGAA CGGGACGCAG CAGGCGCGCC CCGGGACTCT	420
GGCGATCCCC AAGCCAGACA GTCCCCGGAG CGGGAGGAGG GCGGCGGGCC TCGGAGTCGC	480
GAAGCCCCGT CGCGACTGCT GCTCTGGAG CAGGAGCTCA AGAOGGTAC ACCTCGCTG	540
CTCAAGAGGC TCAAGGAGCG TTGCTGGAC ACGCTGTTGG AGGCTGTGGA GTCCCGAGGC	600
5 GGGGTACCGG GCGGCTGGGT GCTGGTGGCG CGCGCCGACCC TCCGCTTGGG CGGCCAGCCC	660
GCGCCACCGC AGCTGCTGCT CGGCCGCTC TTCCGCTGGC CAGACCTGCA GCACGCAGTG	720
GAGCTGAAAC CCCTGTGGGG CTGCCACAGC TTTACCGCCG CGGCCGACGG GCCCACGGTG	780
TGTTGCAACC CCTACCACCT CAGCCGGCTC TGCGGGCCAG AATCACCGCC GCCCCCCTAT	840
TCTCGGCTGT CTCCCTCTGA CCAGTACAAG CCACTGGATC TGTCCGATTAC TACATTGTCT	900
10 TACACTGAAA CCGAGGCCAC CAACTCCCTC ATCACTGCTC CGGGTGARTT CTCAGATGCC	960
AGCATGTCTC CGGATGCCAC CAAGCCGAGC CACTGGTGCA GCGTGGCGTA CTGGGAGCAC	1020
CGGACACGCG TGGGCGGCCT CTATGCGGTG TACGACCAGG CTGTCAGCAT TTTCTACGAC	1080
CTACCTCAGG GCAGCGGCCT CTGCCCTGGC CAGCTAACCC TGGAGCAGCG CAGTGAGTCG	1140
GTGCGCGCA CGCGCAGCAA GATCGGTTTT GGCATACTGC TCAGCAAGGA GCCAGACGGC	1200
15 GTGTGGGCCT ACAACCGGGG CGAGCACCCCC ATCTCGTCA ACTCCCCGAC GCTGGATGCG	1260
CCCGGAGGCC GCGCCCTGGT CGTGGCAAG GTGCCACCGG GTTACTCCAT CAAGGTGTT	1320
GACTTGAGC GCTCAGGGCT GCTGAGCAC GCAGACGCCG CTCACGGCCC CTACGACCCG	1380
CACAGTGTGC GCATCAGCTT CGCCAAGGGC TGGGGACCTT GCTACTCGCG ACAGTTCATC	1440
ACCTCCIGCC CCTGTTGGCT GGAGATCCTA CTCAACAAACC ACAGATAG	1488

20

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1270 base pairs
- 25 (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

- 51 -

	AAAAGAACGA ATCCAGCACC AAAACGTGCT ACAACATGGA TGAACITTCGA CCACATGAAA	60
	GAAGAAGCCA GCCACAAAAG GCCATATATT GTATGAAATG AAATGTCCAG AATGGGCAAA	120
	CCCATAGAGA CACAAAATC TCGGCCACCT CCCTACTCTC GGCTGTCTCC TCGCGACGAG	180
	TACAAGCCAC TGGATCTGTC CGATTCCACA TTGTCTTACA CTGAAACGGA GGCTACCAAC	240
5	TCCCTCATCA CTGCTCCGGG TGAATTCTCA GACGCCAGCA TGTCTCCGGA CGCCACCAAG	300
	CCGAGCCACT GGTGCAGCGT GGCGTACTGG GAGCACCGGA CGCGCGTGGG CCGCCTCTAT	360
	GCGGTGTACG ACCAGGCCGT CACCATCTTC TACGACCTAC CTCAGGGCAG CGGCTTCTGC	420
	CTGGGCCAGC TCAACCTIGGA GCAGCGCAGC GAGTCGGTGC GGCGAACGCG CAGCAAGATC	480
	GGCTTCGGCA TCCTGCTCAG CAAGGAGCCC GACGGCGTGT GGGCTACAA CCGCGCGAG	540
10	CACCCCCATCT TCGTCAACTC CCCGACGCTG GACGCGCCCG GCGGCCGCGC CCTGGTGTG	600
	CGCAAGGTGC CCCCCGGCTA CTCCATCAAG GTGTTCGACT TCGAGCGCTC GGGCCTGCAG	660
	CACCGGCCCG AGCCCGACGC CGCCGACGGC CCCTACGACC CCAACAGCGT CGCGATCAGC	720
	TTCGCCAAGG GCTGGGGGCC CTGCTACTCC CGGCAGTTCA TCACCTCCTG CCCCCTGCTGG	780
	CTGGAGATCC TCCTCAACAA CCCCAGATAG TGGCGGCCCG GGCGGGAGGG GCGGGTGGGA	840
15	GGCCGCGGCC ACCGCCACCT GCCGGCCTCG AGAGGGCCG ATGCCAGAG ACACAGCCCC	900
	CA CGGACAAA ACCCCCCAGA TATCATCTAC CTAGATTAA TATAAAGTTT TATATATTAT	960
	ATGGAAATAT ATATTATACT TGTAATTATG GAGTCATTAA TACAATGTAA TTATTTATGT	1020
	ATGGTGCAAT GTGTGTATAT GGACAAAACA AGAAAGACGC ACTTTGGCTT ATAATTCTTT	1080
	CAATACAGAT ATATTTCTT TCTCTTCTTC CTTCTCTTC CTTACTTTTT ATATATATAT	1140
20	ATAAAGAAAA TGATACAGCA GAGCTAGGTG GAAAAGCCTG GGTTGGTGT ATGGTTTTTG	1200
	AGATATTAAT GCCCAGACAA AAAGCTAATA CCAGTCACTC GATAATAAAG TATTCGCATT	1260
	ATAAAAAAGA	1270

(2) INFORMATION FOR SEQ ID NO:5:

25

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 235 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

30 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

- 52 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Met Ser Arg Met Gly Lys Pro Ile Glu Thr Gln Lys Ser Pro Pro Pro
 1 5 10 15

5 Pro Tyr Ser Arg Leu Ser Pro Arg Asp Glu Tyr Lys Pro Leu Asp Leu
 20 25 30

Ser Asp Ser Thr Leu Ser Tyr Thr Glu Ala Thr Asn Ser Leu
 35 40 45

Ile Thr Ala Pro Gly Glu Phe Ser Asp Ala Ser Met Ser Pro Asp Ala
 10 50 55 60

Thr Lys Pro Ser His Trp Cys Ser Val Ala Tyr Trp Glu His Arg Thr
 65 70 75 80

Arg Val Gly Arg Leu Tyr Ala Val Tyr Asp Gln Ala Val Ser Ile Phe
 85 90 95

15 Tyr Asp Leu Pro Gln Gly Ser Gly Phe Cys Leu Gly Gln Leu Asn Leu
 100 105 110

Glu Gln Arg Ser Glu Ser Val Arg Arg Thr Arg Ser Lys Ile Gly Phe
 115 120 125

Gly Ile Leu Leu Ser Lys Glu Pro Asp Gly Val Trp Ala Tyr Asn Arg
 20 130 135 140

Gly Glu His Pro Ile Phe Val Asn Ser Pro Thr Leu Asp Ala Pro Gly
 145 150 155 160

Gly Arg Ala Leu Val Val Arg Lys Val Pro Pro Gly Tyr Ser Ile Lys
 165 170 175

25 Val Phe Asp Phe Glu Arg Ser Gly Leu Gln His Ala Pro Glu Pro Asp
 180 185 190

Ala Ala Asp Gly Pro Tyr Asp Pro Asn Ser Val Arg Ile Ser Phe Ala
 195 200 205

Lys Gly Trp Gly Pro Cys Tyr Ser Arg Gln Phe Ile Thr Ser Cys Pro
 30 210 215 220

Cys Trp Leu Glu Ile Leu Leu Asn Asn Pro Arg
 225 230 235

- 53 -

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 465 amino acids
- 5 (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Met Asn Val Thr Ser Leu Phe Ser Phe Thr Ser Pro Ala Val Lys Arg
1 5 10 15

15 Leu Leu Gly Trp Lys Gln Gly Asp Glu Glu Glu Lys Trp Ala Glu Lys
20 25 30

Ala Val Asp Ala Leu Val Lys Lys Leu Lys Lys Lys Gly Ala Met
35 40 45

Glu Glu Leu Glu Lys Ala Leu Ser Cys Pro Gly Gln Pro Ser Asn Cys
20 50 55 60

Val Thr Ile Pro Arg Ser Leu Asp Gly Arg Leu Gln Val Ser His Arg
65 70 75 80

Lys Gly Leu Pro His Val Ile Tyr Cys Arg Val Trp Arg Trp Pro Asp
85 90 95

25 Leu Gln Ser His His Glu Leu Lys Pro Leu Glu Cys Cys Glu Phe Pro
100 105 110

Phe Gly Ser Lys Gln Lys Glu Val Cys Ile Asn Pro Tyr His Tyr Lys
115 120 125

Arg Val Glu Ser Pro Val Leu Pro Pro Val Leu Val Pro Arg His Ser
30 130 135 140

Glu Tyr Asn Pro Gln His Ser Leu Leu Ala Gln Phe Arg Asn Leu Gly
145 150 155 160

- 54 -

Gln Asn Glu Pro His Met Pro Leu Asn Ala Thr Phe Pro Asp Ser Phe
 165 170 175
 Gln Gln Pro Asn Ser His Pro Phe Pro His Ser Pro Asn Ser Ser Tyr
 180 185 190
 5 Pro Asn Ser Pro Gly Ser Ser Ser Thr Tyr Pro His Ser Pro Thr
 195 200 205
 Ser Ser Asp Pro Gly Ser Pro Phe Gln Met Pro Ala Asp Thr Pro Pro
 210 215 220
 Pro Ala Tyr Leu Pro Pro Glu Asp Pro Met Thr Gln Asp Gly Ser Gln
 10 225 230 235 240
 Pro Met Asp Thr Asn Met Met Ala Pro Pro Leu Pro Ser Glu Ile Asn
 245 250 255
 Arg Gly Asp Val Gln Ala Val Ala Tyr Glu Glu Pro Lys His Trp Cys
 260 265 270
 15 Ser Ile Val Tyr Tyr Glu Leu Asn Asn Arg Val Gly Glu Ala Phe His
 275 280 285
 Ala Ser Ser Thr Ser Val Leu Val Asp Gly Phe Thr Asp Pro Ser Asn
 290 295 300
 Asn Lys Asn Arg Phe Cys Leu Gly Leu Leu Ser Asn Val Asn Arg Asn
 20 305 310 315 320
 Ser Thr Ile Glu Asn Thr Arg Arg His Ile Gly Lys Gly Val His Leu
 325 330 335
 Tyr Tyr Val Gly Gly Glu Val Tyr Ala Glu Cys Leu Ser Asp Ser Ser
 340 345 350
 25 Ile Phe Val Gln Ser Arg Asn Cys Asn Tyr His His Gly Phe His Pro
 355 360 365
 Thr Thr Val Cys Lys Ile Pro Ser Gly Cys Ser Leu Lys Ile Phe Asn
 370 375 380
 Asn Gln Glu Phe Ala Gln Leu Leu Ala Gln Ser Val Asn His Gly Phe
 30 385 390 395 400
 Glu Thr Val Tyr Glu Leu Thr Lys Met Cys Thr Ile Arg Met Ser Phe
 405 410 415

- 55 -

Val Lys Gly Trp Gly Ala Glu Tyr His Arg Gln Asp Val Thr Ser Thr
420 425 430
Pro Cys Trp Ile Glu Ile His Leu His Gly Pro Leu Gln Trp Leu Asp
435 440 445
5 Lys Val Leu Thr Gln Met Gly Ser Pro His Asn Pro Ile Ser Ser Val
450 455 460
Ser
465

10 (2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 467 amino acids
(B) TYPE: amino acid
15 (C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Met Ser Ser Ile Leu Pro Phe Thr Pro Pro Val Val Lys Arg Leu Leu
1 5 10 15
Gly Trp Lys Lys Ser Ala Gly Gly Ser Gly Gly Ala Gly Gly Gly Glu
25 20 25 30
Gln Asn Gly Gln Glu Glu Lys Trp Cys Gln Lys Ala Val Lys Ser Leu
35 40 45
Val Lys Lys Leu Lys Lys Thr Gly Arg Leu Asp Glu Leu Glu Lys Ala
50 55 60
30 Ile Thr Thr Gln Asn Cys Asn Thr Lys Cys Val Thr Ile Pro Ser Thr
65 70 75 80
Cys Ser Glu Ile Trp Gly Leu Ser Thr Ala Asn Thr Val Asp Gln Trp

- 56 -

	85	90	95
Asp Thr Thr Gly Leu Tyr Ser Phe Ser Glu Gln Thr Arg Ser Leu Asp			
	100	105	110
Gly Arg Leu Gln Val Ser His Arg Lys Gly Leu Pro His Val Ile Tyr			
5	115	120	125
Cys Arg Leu Trp Arg Trp Pro Asp Leu His Ser His His Glu Leu Lys			
	130	135	140
Ala Ile Glu Asn Cys Glu Tyr Ala Phe Asn Leu Lys Lys Asp Glu Val			
	145	150	155
10	160		
Cys Val Asn Pro Tyr His Tyr Gln Arg Val Glu Thr Pro Val Leu Pro			
	165	170	175
Pro Val Leu Val Pro Arg His Thr Glu Ile Leu Thr Glu Leu Pro Pro			
	180	185	190
Leu Asp Asp Tyr Thr His Ser Ile Pro Glu Asn Thr Asn Phe Pro Ala			
15	195	200	205
Gly Ile Glu Pro Gln Ser Asn Tyr Ile Pro Glu Thr Pro Pro Pro Gly			
	210	215	220
Tyr Ile Ser Glu Asp Gly Glu Thr Ser Asp Gln Gln Leu Asn Gln Ser			
	225	230	235
20	240		
Met Asp Thr Gly Ser Pro Ala Glu Leu Ser Pro Thr Thr Leu Ser Pro			
	245	250	255
Val Asn His Ser Leu Asp Leu Gln Pro Val Thr Tyr Ser Glu Pro Ala			
	260	265	270
Phe Trp Cys Ser Ile Ala Tyr Tyr Glu Leu Asn Gln Arg Val Gly Glu			
25	275	280	285
Thr Phe His Ala Ser Gln Pro Ser Leu Thr Val Asp Gly Phe Thr Asp			
	290	295	300
Pro Ser Asn Ser Glu Arg Phe Cys Leu Gly Leu Leu Ser Asn Val Asn			
	305	310	315
30	320		
Arg Asn Ala Thr Val Glu Met Thr Arg Arg His Ile Gly Arg Gly Val			
	325	330	335
Arg Leu Tyr Tyr Ile Gly Gly Glu Val Phe Ala Glu Cys Leu Ser Asp			

- 57 -

	340	345	350
	Ser Ala Ile Phe Val Gln Ser Pro Asn Cys Asn Gln Arg Tyr Gly Trp		
	355	360	365
	His Pro Ala Thr Val Cys Lys Ile Pro Pro Gly Cys Asn Leu Lys Ile		
5	370	375	380
	Phe Asn Asn Gln Glu Phe Ala Ala Leu Leu Ala Gln Ser Val Asn Gln		
	385	390	395
	Gly Phe Glu Ala Val Tyr Gln Leu Thr Arg Met Cys Thr Ile Arg Met		
	405	410	415
10	Ser Phe Val Lys Gly Trp Gly Ala Glu Tyr Arg Arg Gln Thr Val Thr		
	420	425	430
	Ser Thr Pro Cys Trp Ile Glu Leu His Leu Asn Gly Pro Leu Gln Trp		
	435	440	445
	Leu Asp Lys Val Leu Thr Gln Met Gly Ser Pro Ser Val Arg Cys Ser		
15	450	455	460
	Ser Met Ser		
	465		

(2) INFORMATION FOR SEQ ID NO:8:

20

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 425 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- 25 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

30

Met Ser Ser Ile Leu Pro Phe Thr Pro Pro Ile Val Lys Arg Leu Leu			
1	5	10	15

- 58 -

Gly Trp Lys Lys Gly Glu Gln Asn Gly Gln Glu Glu Lys Trp Cys Glu
 20 25 30

Lys Ala Val Lys Ser Leu Val Lys Lys Leu Lys Lys Thr Gly Gln Leu
 35 40 45

5 Asp Glu Leu Glu Lys Ala Ile Thr Thr Gln Asn Val Asn Thr Lys Cys
 50 55 60

Ile Thr Ile Pro Arg Ser Leu Asp Gly Arg Leu Gln Val Ser His Arg
 65 70 75 80

Lys Gly Leu Pro His Val Ile Tyr Cys Arg Leu Trp Arg Trp Pro Asp
 10 85 90 95

Leu His Ser His His Glu Leu Arg Ala Met Glu Leu Cys Glu Phe Ala
 100 105 110

Phe Asn Met Lys Lys Asp Glu Val Cys Val Asn Pro Tyr His Tyr Gln
 115 120 125

15 Arg Val Glu Thr Pro Val Leu Pro Pro Val Leu Val Pro Arg His Thr
 130 135 140

Glu Ile Pro Ala Glu Phe Pro Pro Leu Asp Asp Tyr Ser His Ser Ile
 145 150 155 160

Pro Glu Asn Thr Asn Phe Pro Ala Gly Ile Glu Pro Gln Ser Asn Ile
 20 165 170 175

Pro Glu Thr Pro Pro Gly Tyr Leu Ser Glu Asp Gly Glu Thr Ser
 180 185 190

Asp His Gln Met Asn His Ser Met Asp Ala Gly Ser Pro Asn Leu Ser
 195 200 205

25 Pro Asn Pro Met Ser Pro Ala His Asn Asn Leu Asp Leu Gln Pro Val
 210 215 220

Thr Tyr Cys Glu Pro Ala Phe Trp Cys Ser Ile Ser Tyr Tyr Glu Leu
 225 230 235 240

Asn Gln Arg Val Gly Glu Thr Phe His Ala Ser Gln Pro Ser Met Thr
 30 245 250 255

Val Asp Gly Phe Thr Asp Pro Ser Asn Ser Glu Arg Phe Cys Leu Gly
 260 265 270

- 59 -

	Leu Leu Ser Asn Val Asn Arg Asn Ala Ala Val Glu Leu Thr Arg Arg	
275	280	285
	His Ile Gly Arg Gly Val Arg Leu Tyr Tyr Ile Gly Gly Glu Val Phe	
290	295	300
5	Ala Glu Cys Leu Ser Asp Ser Ala Ile Phe Val Gln Ser Pro Asn Cys	
305	310	315
	Asn Gln Arg Tyr Gly Trp His Pro Ala Thr Val Cys Lys Ile Pro Pro	
	325	330
		335
	Gly Cys Asn Leu Lys Ile Phe Asn Asn Gln Glu Phe Ala Ala Leu Leu	
10	340	345
		350
	Ala Gln Ser Val Asn Gln Gly Phe Glu Ala Val Tyr Gln Leu Thr Arg	
	355	360
		365
	Met Cys Thr Ile Arg Met Ser Phe Val Lys Gly Trp Gly Ala Glu Tyr	
	370	375
		380
15	Arg Arg Gln Thr Val Thr Ser Thr Pro Cys Trp Ile Glu Leu His Leu	
385	390	395
		400
	Asn Gly Pro Leu Gln Trp Leu Asp Lys Val Leu Thr Gln Met Gly Ser	
	405	410
		415
	Pro Ser Ile Arg Cys Ser Ser Val Ser	
20	420	425

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH: 552 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

- 60 -

Met Asp Asn Met Ser Ile Thr Asn Thr Pro Thr Ser Asn Asp Ala Cys
 1 5 10 15
 Leu Ser Ile Val His Ser Leu Met Cys His Arg Gln Gly Gly Glu Ser
 20 25 30
 5 Glu Thr Phe Ala Lys Arg Ala Ile Glu Ser Leu Val Lys Lys Leu Lys
 35 40 45
 Glu Lys Lys Asp Glu Leu Asp Ser Leu Ile Thr Ala Ile Thr Thr Asn
 50 55 60
 Gly Ala His Pro Ser Lys Cys Val Thr Ile Gln Arg Thr Leu Asp Gly
 10 65 70 75 80
 Arg Leu Gln Val Ala Gly Arg Lys Gly Phe Pro His Val Ile Tyr Ala
 85 90 95
 Arg Leu Trp Arg Trp Pro Asp Leu His Lys Asn Glu Leu Lys His Val
 100 105 110
 15 Lys Tyr Cys Gln Tyr Ala Phe Asp Leu Lys Cys Asp Ser Val Cys Val
 115 120 125
 Asn Pro Tyr His Tyr Glu Arg Val Val Ser Pro Gly Ile Asp Leu Ser
 130 135 140
 Gly Leu Thr Leu Gln Ser Asn Ala Pro Ser Ser Met Met Val Lys Asp
 20 145 150 155 160
 Glu Tyr Val His Asp Phe Glu Gly Gln Pro Ser Leu Ser Thr Glu Gly
 165 170 175
 His Ser Ile Gln Thr Ile Gln His Pro Pro Ser Asn Arg Ala Ser Thr
 180 185 190
 25 Glu Thr Tyr Ser Thr Pro Ala Leu Leu Ala Pro Ser Glu Ser Asn Ala
 195 200 205
 Thr Ser Thr Ala Asn Phe Pro Asn Ile Pro Val Ala Ser Thr Ser Gln
 210 215 220
 Pro Ala Ser Ile Leu Gly Gly Ser His Ser Glu Gly Leu Leu Gln Ile
 30 225 230 235 240
 Ala Ser Gly Pro Gln Pro Gly Gln Gln Asn Gly Phe Thr Gly Gln
 245 250 255

- 61 -

Pro Ala Thr Tyr His His Asn Ser Thr Thr Thr Trp Thr Gly Ser Arg
 260 265 270
 Thr Ala Pro Tyr Thr Pro Asn Leu Pro His His Gln Asn Gly His Leu
 275 280 285
 5 Gln His His Pro Pro Met Pro Pro His Pro Gly His Tyr Trp Pro Val
 290 295 300
 His Asn Glu Leu Ala Phe Gln Pro Pro Ile Ser Asn His Pro Ala Pro
 305 310 315 320
 Glu Tyr Trp Cys Ser Ile Ala Tyr Phe Glu Met Asp Val Gln Val Gly
 10 325 330 335
 Glu Thr Phe Lys Val Pro Ser Ser Cys Pro Ile Val Thr Val Asp Gly
 340 345 350
 Tyr Val Asp Pro Ser Gly Gly Asp Arg Phe Cys Leu Gly Gln Leu Ser
 355 360 365
 15 Asn Val His Arg Thr Glu Ala Ile Glu Arg Ala Arg Leu His Ile Gly
 370 375 380
 Lys Gly Val Gln Leu Glu Cys Lys Gly Glu Gly Asp Val Trp Val Arg
 385 390 395 400
 Cys Leu Ser Asp His Ala Val Phe Val Gln Ser Tyr Tyr Leu Asp Arg
 20 405 410 415
 Glu Ala Gly Arg Ala Pro Gly Asp Ala Val His Lys Ile Tyr Pro Ser
 420 425 430
 Ala Tyr Ile Lys Val Phe Asp Leu Arg Gln Cys His Arg Gln Met Gln
 435 440 445
 25 Gln Gln Ala Ala Thr Ala Gln Ala Ala Ala Ala Gln Ala Ala Ala
 450 455 460
 Val Ala Gly Asn Ile Pro Gly Pro Gly Ser Val Gly Gly Ile Ala Pro
 465 470 475 480
 Ala Ile Ser Leu Ser Ala Ala Ala Gly Ile Gly Val Asp Asp Leu Arg
 30 485 490 495
 Arg Leu Cys Ile Leu Arg Met Ser Phe Val Lys Gly Trp Gly Pro Asp
 500 505 510

- 62 -

Tyr Pro Arg Gln Ser Ile Lys Glu Thr Pro Cys Trp Ile Glu Ile His
 515 520 525
 Leu His Arg Ala Leu Gln Leu Leu Asp Glu Val Leu His Thr Met Pro
 530 535 540
 5 Ile Ala Asp Pro Gln Pro Leu Asp
 545 550

(2) INFORMATION FOR SEQ ID NO:10:

10 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 465 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

15

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

20 Met Thr Ser Met Ala Ser Leu Phe Ser Phe Thr Ser Pro Ala Val Lys
 1 5 10 15
 Arg Leu Leu Gly Trp Lys Gln Gly Asp Glu Glu Glu Lys Trp Ala Glu
 20 25 30
 Lys Ala Val Asp Ala Leu Val Lys Lys Leu Lys Lys Lys Gly Ala
 25 35 40 45
 Met Glu Glu Leu Glu Lys Ala Leu Ser Ser Pro Gly Gln Pro Ser Lys
 50 55 60
 Cys Val Thr Ile Pro Arg Ser Leu Asp Gly Arg Leu Gln Val Ser His
 65 70 75 80
 30 Arg Lys Gly Leu Pro His Val Ile Tyr Cys Arg Val Trp Arg Trp Pro
 85 90 95
 Asp Leu Gln Ser His His Glu Leu Lys Pro Leu Asp Ile Cys Glu Phe

- 63 -

	100	105	110
	Pro Phe Gly Ser Lys Gln Lys Glu Val Cys Ile Asn Pro Tyr His Tyr		
	115	120	125
	Lys Arg Val Glu Ser Pro Val Leu Pro Pro Val Leu Val Pro Arg His		
5	130	135	140
	Asn Glu Phe Asn Pro Gln His Ser Leu Leu Val Gln Phe Arg Asn Leu		
	145	150	155
	Ser His Asn Glu Pro His Met Pro Gln Asn Ala Thr Phe Pro Asp Ser		
	165	170	175
10	Phe His Gln Pro Asn Asn Ala Pro Phe Pro Leu Ser Pro Asn Ser Pro		
	180	185	190
	Tyr Pro Pro Pro Ala Ser Ser Thr Tyr Pro Asn Ser Pro Ala Ser		
	195	200	205
	Ser Gly Pro Gly Ser Pro Phe Gln Leu Pro Ala Asp Thr Pro Pro Pro		
15	210	215	220
	Ala Tyr Met Pro Pro Asp Asp Gln Met Ala Pro Asp Asn Ser Gln Pro		
	225	230	235
	Met Asp Thr Ser Ser Asn Met Ile Pro Gln Thr Met Pro Ser Ile Ser		
	245	250	255
20	Ser Arg Asp Val Gln Pro Val Ala Tyr Glu Glu Pro Lys His Trp Cys		
	260	265	270
	Ser Ile Val Tyr Tyr Glu Leu Asn Asn Arg Val Gly Glu Ala Phe His		
	275	280	285
	Ala Ser Ser Thr Ser Val Leu Val Asp Gly Phe Thr Asp Pro Ser Asn		
25	290	295	300
	Asn Lys Ser Arg Phe Cys Leu Gly Leu Leu Ser Asn Val Asn Arg Asn		
	305	310	315
	Ser Thr Ile Glu Asn Thr Arg Arg His Ile Gly Lys Gly Val His Leu		
	325	330	335
30	Tyr Tyr Val Gly Gly Glu Val Tyr Ala Glu Cys Leu Ser Asp Ser Ser		
	340	345	350
	Ile Phe Val Gln Ser Arg Asn Cys Asn Phe His His Gly Phe His Pro		

- 64 -

355 360 365
Thr Thr Val Cys Lys Ile Pro Ser Ser Cys Ser Leu Lys Ile Phe Asn
370 375 380
Asn Gln Glu Phe Ala Gln Leu Leu Ala Gln Ser Val Asn His Gly Phe
5 385 390 395 400
Glu Ala Val Tyr Glu Leu Thr Lys Met Cys Thr Ile Arg Met Ser Phe
 405 410 415
Val Lys Gly Trp Gly Ala Glu Tyr His Arg Gln Asp Val Thr Ser Thr
 420 425 430
10 Pro Cys Trp Ile Glu Ile His Leu His Gly Pro Leu Gln Trp Leu Asp
 435 440 445
Lys Val Leu Thr Gln Met Gly Ser Pro Leu Asn Pro Ile Ser Ser Val
 450 455 460
Ser
15 465

CLAIMS

1. An isolated nucleic acid molecule selected from the group consisting of
 - (a) nucleic acid molecules which hybridize under stringent conditions to a molecule consisting of the nucleic acid sequence of SEQ ID NO:1 and which code for a polypeptide which inhibits TGF- β superfamily signalling,
 - (b) nucleic acid molecules that differ from the nucleic acid molecules of (a) in codon sequence due to the degeneracy of the genetic code, and
 - (c) complements of (a) and (b).
- 10 2. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises the nucleic acid sequence of SEQ ID NO:3.
3. The isolated nucleic acid molecule of claim 2, wherein the isolated nucleic acid molecule consists of the nucleic acid sequence of SEQ ID NO:3.
- 15 4. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule consists of the nucleic acid sequence of SEQ ID NO:1.
5. An isolated nucleic acid molecule selected from the group consisting of (a) a unique fragment of SEQ ID NO:3 between 20 and 1487 nucleotides in length, and (b) complements of “(a)”, provided that the nucleic acid molecule excludes sequences consisting only of SEQ ID NO:4 or fragments thereof.
- 20 6. The isolated nucleic acid molecule of claim 5, wherein the isolated nucleic acid molecule is a unique fragment of SEQ ID NO:3 selected from the group consisting of at least 22 contiguous nucleotides, at least 24 contiguous nucleotides, at least 26 contiguous nucleotides, at least 28 contiguous nucleotides, at least 30 contiguous nucleotides, at least 35 contiguous nucleotides, and at least 40 contiguous nucleotides.
- 25 7. The isolated nucleic acid molecule of claim 5, wherein the isolated nucleic acid molecule consists of between 20 and 32 contiguous nucleotides.

8. An expression vector comprising the isolated nucleic acid molecule of claims 1, 2, 3, 4, 5, 6, or 7 operably linked to a promoter.

9. A host cell transformed or transfected with the expression vector of claim 8.

5

10. A transgenic non-human animal comprising the expression vector of claim 8.

11. The transgenic non-human animal of claim 10, comprising a conditional Smad6 expression vector.

10

12. A transgenic non-human animal which has reduced expression of Smad6 nucleic acid molecules.

15

13. The transgenic non-human animal of claim 12, comprising a Smad6 gene disrupted by homologous recombination.

14. The transgenic non-human animal of claim 12, comprising a conditional Smad6 gene disruption.

20

15. The transgenic non-human animal of claim 12, comprising a trans-acting negative regulator of Smad6 expression.

16. An isolated polypeptide encoded by the isolated nucleic acid molecule of claim 1, 2, 3, or 4, wherein the polypeptide has TGF- β superfamily signalling inhibitory activity.

25

17. The isolated polypeptide of claim 16, wherein the isolated polypeptide consists of the amino acid sequence of SEQ ID NO:2.

30

18. The isolated polypeptide of claim 16, wherein the isolated polypeptide consists of a functional fragment or variant.

19. An isolated polypeptide which binds selectively a polypeptide encoded by the isolated

nucleic acid molecule of claim 1, 2, 3, or 4, provided that the isolated polypeptide is not a polypeptide selected from the group consisting of TGF- β receptor, activin receptor and BMP receptor.

5 20. The isolated polypeptide of claim 19, wherein the isolated polypeptide binds to an epitope defined by a polypeptide consisting of the amino acid sequence of SEQ ID NO:2.

10 21. The isolated polypeptide of claim 19, wherein the isolated polypeptide is an antibody fragment selected from the group consisting of a Fab fragment, a F(ab)₂ fragment or a fragment including a CDR3 region selective for a Smad6 polypeptide.

22. The isolated polypeptide of claim 19, wherein the isolated polypeptide is a monoclonal antibody, a humanized antibody or a chimeric antibody.

15 23. An isolated complex of polypeptides comprising:
a TGF- β superfamily receptor or receptor complex, bound to a polypeptide as claimed in
claim 16.

20 24. The isolated complex of polypeptides of claim 23, wherein the polypeptide as claimed in
claim 16 consists of the amino acid sequence of SEQ ID NO:2.

25. The isolated complex of claim 23, wherein the receptor or receptor complex is selected
from the group consisting of T β RI, BMPR-IA, BMPR-IB, ActR-IA, a complex of T β RI and
T β RII, a complex of BMPR-IA and BMPR-II, a complex of BMPR-IB and BMPR-II, a complex
of ActR-IA and BMPR-II and a complex of ActR-IA and ActR-II.

26. A method for reducing TGF- β superfamily signal transduction in a mammalian cell,
comprising
30 contacting the mammalian cell with an amount of the isolated nucleic acid molecule of
claim 1 or an expression product thereof effective to reduce TGF- β superfamily signal
transduction in the mammalian cell.

27. A method for reducing phosphorylation of a pathway restricted Smad polypeptide in a mammalian cell, comprising

contacting the mammalian cell with an amount of the isolated nucleic acid molecule of claim 1 or an expression product thereof effective to reduce phosphorylation of the pathway

5 restricted Smad polypeptide in the mammalian cell.

28. The method of claim 27, wherein the pathway specific Smad polypeptide is selected from the group consisting of Smad1 and Smad2.

10 29. A method for modulating the proliferation of a cancer cell, the proliferation of which is altered by TGF- β superfamily signal transduction, comprising

contacting the cancer cell with an amount of an isolated nucleic acid molecule of claim 1 or an expression product thereof, effective to modulate the proliferation of the cancer cell.

15 30. A method of increasing TGF- β superfamily signal transduction in a cell comprising
contacting the cell with an amount of an agent that selectively binds to an isolated nucleic acid molecule of claim 1 or an isolated Smad polypeptide expression product thereof, effective to increase the TGF- β superfamily signal transduction in the cell.

20 31. The method of claim 30 wherein the TGF- β superfamily signal transduction is mediated by a TGF β superfamily ligand selected from the group consisting of TGF- β 1, activin, VgI, BMP-4 and BMP-7.

32. The method of claim 31, wherein the agent is an antisense nucleic acid.

25

33. The method of claim 31, wherein the agent is a polypeptide.

34. The method of claim 33, wherein the polypeptide is selected from the group consisting of an antibody which binds an epitope defined by a polypeptide comprising the amino acid sequence of SEQ ID NO:2 and a dominant negative variant of a Smad6 polypeptide.

30 35. A composition comprising:

the polypeptide of claim 16, and
a pharmaceutically acceptable carrier.

36. A method for decreasing Smad6 TGF- β superfamily inhibitory activity in a subject
5 comprising
administering to a subject in need of such treatment an agent that selectively binds to an isolated nucleic acid molecule of claim 1 or an expression product thereof, in an amount effective to decrease Smad6 TGF- β superfamily inhibitory activity in the subject.
- 10 37. The method of claim 36 wherein the TGF- β superfamily inhibitory activity is inhibition of TGF- β superfamily signal transduction mediated by a TGF β superfamily ligand selected from the group consisting of TGF- β 1, activin, Vg1, BMP-4 and BMP-7.
- 15 38. The method of claim 37, wherein the agent is an antisense nucleic acid.
39. The method of claim 37, wherein the agent is a polypeptide.
40. The method of claim 39, wherein the polypeptide is selected from the group consisting of an antibody which binds an epitope defined by a polypeptide comprising the amino acid sequence of SEQ ID NO:2 and a dominant negative variant of a Smad6 polypeptide.
- 20 41. A method for treating a condition characterized by abnormal BMP activity, comprising administering to a subject in need of such treatment an effective amount of Smad6 or a Smad6 agonist or antagonist sufficient to restore the BMP activity to normal.
- 25 42. The method of claim 41, wherein the condition is selected from the group consisting of ossification of the posterior longitudinal ligament and ossification of the ligament flavum.
43. A method for treating a condition characterized by abnormal TGF- β activity, comprising
30 administering to a subject in need of such treatment an effective amount of Smad6 or a Smad6 agonist or antagonist sufficient to restore the TGF- β activity to normal.

44. The method of claim 43, wherein the condition is a fibrotic condition selected from the group consisting of liver fibrosis, kidney fibrosis, lung fibrosis, skin fibrosis, arterial fibrosis, central nervous system fibrosis, and other fibrotic diseases.

5 45. The method of claim 44, wherein the fibrotic condition is selected from the group consisting of cirrhosis, veno-occlusive disease, glomerulonephritis, diabetic nephropathy, allograft rejection, HIV nephropathy, idiopathic fibrosis, autoimmune fibrosis, systemic sclerosis, keloids, hypertrophic burn scars, eosinophilia-myalgia syndrome, vascular restenosis, atherosclerosis, intraocular fibrosis, rheumatoid arthritis and nasal polypsis.

10

46. A method for modulating the expression of cyclin A, comprising contacting a cell with Smad6 or an agonist or antagonist thereof, in an amount effective to modulate the expression of cyclin A.

15 47. The method of claim 46, wherein the cell is contacted with Smad6 or an agonist thereof, and wherein the expression of cyclin A is increased.

48. The method of claim 46, wherein the cell is contacted with an antagonist of Smad6, and wherein the expression of cyclin A is decreased.

20

49. The method of claim 48, wherein the antagonist of Smad6 is selected from the group consisting of antibodies to Smad6, dominant negative variants of Smad6 and Smad6 antisense nucleic acids.

25 50. A method for identifying lead compounds for a pharmacological agent useful in the diagnosis or treatment of disease associated with Smad6 TGF- β superfamily inhibitory activity, comprising

forming a mixture comprising a Smad6 polypeptide, a receptor or receptor complex for a TGF- β superfamily member, and a candidate pharmacological agent,

30 incubating the mixture under conditions which, in the absence of the candidate pharmacological agent, permit a first amount of specific binding of the TGF- β superfamily receptor or receptor complex by the Smad6 polypeptide, and

- detecting a test amount of the specific binding of the TGF- β superfamily receptor or receptor complex by the Smad6 polypeptide, wherein reduction of the test amount of specific binding relative to the first amount of specific binding indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which disrupts the
- 5 Smad6 TGF- β superfamily signal transduction inhibitory activity, and wherein increase of the test amount of specific binding relative to the first amount of specific binding indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which enhances the Smad6 TGF- β superfamily signal transduction inhibitory activity.
- 10 51. The method of claim 50, wherein the member of the TGF- β superfamily is selected from the group consisting of TGF- β 1, activin, BMP-4 and BMP-7.
52. A method for identifying lead compounds for a pharmacological agent useful in the diagnosis or treatment of disease associated with Smad6 TGF- β superfamily signal transduction inhibitory activity, comprising
- 15 forming a mixture comprising a Smad6 polypeptide, a receptor or receptor complex for a TGF- β superfamily member, a pathway restricted Smad polypeptide and a candidate pharmacological agent,
- 20 incubating the mixture under conditions which, in the absence of the candidate pharmacological agent, permit a first amount of TGF- β superfamily member induced phosphorylation of the pathway restricted Smad polypeptide, and
- 25 detecting a test amount of TGF- β superfamily member induced phosphorylation of the pathway restricted Smad polypeptide, wherein reduction of the test amount of the phosphorylation of the pathway restricted Smad polypeptide relative to the first amount of the phosphorylation of the pathway restricted Smad polypeptide indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which enhances the TGF- β superfamily signal transduction inhibitory activity of Smad6 and wherein increase of the test amount of the phosphorylation of the pathway restricted Smad polypeptide relative to the first amount of the phosphorylation of the pathway restricted Smad polypeptide indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which disrupts the TGF- β superfamily signal transduction inhibitory activity of Smad6.

53. The method of claim 52, wherein the pathway restricted Smad polypeptide is selected from the group consisting of Smad1 and Smad2.

54. The method of claim 52, wherein the member of the TGF- β superfamily is selected from the group consisting of TGF- β 1, activin, BMP-4 and BMP-7.

55. A method for increasing phosphorylation of Smad3 in a mammalian cell, comprising contacting the mammalian cell with an amount of the isolated nucleic acid molecule of claim 1 or an expression product thereof effective to increase phosphorylation of Smad3 in the mammalian cell.

56. A method for reducing heteromerization of Smad2 with Smad3 or Smad4 in a mammalian cell, comprising contacting the mammalian cell with an amount of the isolated nucleic acid molecule of claim 1 or an expression product thereof effective to reduce heteromerization of Smad2 with Smad3 or Smad4 in the mammalian cell.

Fig. 1a




Fig. 16





Fig. 2



5 / 8




Fig. 3c, d




Fig. 4




Fig. 5




Fig. 6

13/16

T β R-I (TD)	-	+	+
M-Smad4	+	+	+
F-Smad3	+	+	+
M-Smad6	-	-	+






Fig. 4B

SUBSTITUTE SHEET (RULE 26)

14/16

T β R-I (TD)	-	+	+
M-Smad3	+	+	+
F-Smad2	+	+	+
M-Smad6	-	-	+





Fig. 4C

15/16




Fig. 5A

Fig. 5B

Fig. 5C




Fig. 6A




Fig. 6B




Fig. 6C

SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 98/12078

A. CLASSIFICATION OF SUBJECT MATTER					
IPC 6	C12N15/12	C12N15/11	C12N5/10	C07K14/47	C07K16/18
	G01N33/50	A01K67/027	A61K31/70	A61K38/17	A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K G01N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	RIGGINS G ET AL: "Mad-related genes in the human" NATURE GENETICS, vol. 13, July 1996, pages 347-349, XP002078126 cited in the application see "Jv15-1" in figure 1 and Table 1 ---	1-9, 16-25
X	WO 96 24604 A (MILLENNIUM PHARMACEUTICALS INC) 15 August 1996 See legends to figures 34 and 35, and under "rchd534" on page 142 ---	1,5-16, 18-22,35 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "Z" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
22 September 1998	01/10/1998
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. Fax: (+31-70) 340-3016	Authorized officer Lonnoy, O

INTERNATIONAL SEARCH REPORT

Internat I Application No
PCT/US 98/12078

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 97 30065 A (MILLENNIUM PHARMACEUTICALS INC) 21 August 1997 See p.118-122, 125-137, and claims 57-69 ---	1,5-16, 18-22, 26, 29-41, 43,50,51
P,X	WO 97 39105 A (UNIV JOHNS HOPKINS) 23 October 1997 see the whole document ---	1-25,29, 35,41,43
P,X	IMAMURA T ET AL: "Smad6 inhibits signalling by the TGF-beta superfamily" NATURE, vol. 386, 9 October 1997, pages 622-626, XP002078127 see the whole document -----	1-56

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 98/12078

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:

because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claims 26-34, 36-49, 55 and 56, as far as in vivo methods are concerned, are directed to methods of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. Claims Nos.:

because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. Claims Nos.:

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internal Application No

PCT/US 98/12078

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9624604 A	15-08-1996	AU	4921496 A	27-08-1996
		CA	2212731 A	15-08-1996
		EP	0808324 A	26-11-1997
WO 9730065 A	21-08-1997	AU	2124397 A	02-09-1997
WO 9739105 A	23-10-1997	AU	2460097 A	07-11-1997